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A B S T R A C T
The idea of developing automated tools able to deal with the complexity of
clinical information processing dates back to the late 60s: since then, there has
been scope for improving medical care due to the rapid growth of medical
knowledge, and the need to explore new ways of delivering this due to
the shortage of physicians. Clinical decision support systems (CDSS) are
able to aid in the acquisition of patient data and to suggest appropriate
decisions on the basis of the data thus acquired. Many improvements are
envisaged due to the adoption of such systems including: reduction of costs by
faster diagnosis, reduction of unnecessary examinations, reduction of risk of
adverse events and medication errors, increase in the available time for direct
patient care, improved medications and examination prescriptions, improved
patient satisfaction, and better compliance to gold-standard up-to-date clinical
pathways and guidelines.
Logistic regression is a widely used algorithm which frequently appears
in medical literature for building clinical decision support systems: however,
published studies frequently have not followed commonly recommended
procedures for using logistic regression and substantial shortcomings in the
reporting of logistic regression results have been noted. Published literature
has often accepted conclusions from studies which have not addressed the ap-
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propriateness and accuracy of the statistical analyses and other methodological
issues, leading to design flaws in those models and to possible inconsistencies
in the novel clinical knowledge based on such results.
The main objective of this interdisciplinary work is to design a sound
framework for the development of clinical decision support systems. We
propose a framework that supports the proper development of such systems,
and in particular the underlying predictive models, identifying best practices
for each stage of the model’s development.
This framework is composed of a number of subsequent stages: 1) dataset
preparation insures that appropriate variables are presented to the model in a
consistent format, 2) the model construction stage builds the actual regression (or
logistic regression) model determining its coefficients and selecting statistically
significant variables; this phase is generally preceded by a pre-modelling
stage during which model functional forms are hypothesized based on a
priori knowledge 3) the further model validation stage investigates whether the
model could suffer from overfitting, i.e., the model has a good accuracy on
training data but significantly lower accuracy on unseen data, 4) the evaluation
stage gives a measure of the predictive power of the model (making use of
the ROC curve, which allows to evaluate the predictive power of the model
without any assumptions on error costs, and possibly R2 from regressions), 5)
misclassification analysis could suggest useful insights into determining where
the model could be unreliable, 6) implementation stage.
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The proposed framework has been applied to three applications on different
domains, with a view to improve previous research studies.
The first developed model [1] predicts mortality within 28 days of patients
suffering from acute alcoholic hepatitis. The aim of this application is to
build a new predictive model that can be used in clinical practice to identify
patients at greatest risk of mortality in 28 days as they may benefit from
aggressive intervention, and to monitor their progress while in hospital. A
comparison generated by state of the art tools shows an improved predictive
power, demonstrating how an appropriate variables inclusion may result in
an overall better accuracy of the model, which increased by 25% following an
appropriate variables selection process.
The second proposed predictive model [2] is designed to aid the diagnosis of
dementia, as clinicians often experience difficulties in the diagnosis of dementia
due to the intrinsic complexity of the process and lack of comprehensive
diagnostic tools. The aim of this application is to improve on the performance
of a recent application of Bayesian belief networks using an alternative
approach based on logistic regression. The approach based on statistical
variables selection outperformed the model which used variables selected by
domain experts in previous studies. Obtained results outperform considered
benchmarks by 15%.
The third built model [3] predicts the probability of experiencing a certain
symptom among common side-effects in patients receiving chemotherapy. The
newly developed model includes a pre-modelling stage (which was based
15
on previous research studies) and a subsequent regression. The computed
accuracy of results (computed on a daily basis for each cycle of therapy) shows
that the newly proposed approach has increased its predictive power by 19%
when compared to the previously developed model: this has been obtained
by an appropriate usage of available a priori knowledge to pre-model the
functional forms.
As shown by the proposed applications, different aspects of CDSS develop-
ment are subject to substantial improvements: the application of the proposed
framework to different domains leads to more accurate models than the
existing state-of-the-art proposals. The developed framework is capable of
helping researchers to identify and overcome possible pitfalls in their ongoing
research works, by providing them with best practices for each step of the
development process.
An impact on the development of future clinical decision support systems is
envisaged: the usage of an appropriate procedure in model development will
produce more reliable and accurate systems, and will have a positive impact
on the newly produced medical knowledge which may eventually be included
in standard clinical practice.
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Ut in omnibus glorificetur Deus
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I N T R O D U C T I O N
This thesis is the result of a PhD research project funded by the Division
of Computing Science and Mathematics (School of Natural Sciences) at the
University of Stirling, carried out under the supervision of Professor Amir
Hussain (principal supervisor) and Dr David Cairns (second supervisor).
1.1 structure of the thesis
The next chapter 2 gives a general introduction to clinical decision support
systems: moving from definitions and motivations for the work, the role of
knowledge in decision support and techniques used are presented. A brief
analysis of key features and benefits of such systems follows. Finally, the
chapter focuses on logistic regression models which have been developed in
the recent past, identifying common pitfalls and suggesting a possible general
framework for developing and evaluating such systems. Further literature
review is presented throughout the thesis for each specific model which has
been developed.
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1.2 motivation and aims 19
Following chapters are built around the author’s published work. Chapter
3 introduces the proposed framework and the following chapters describe
the development of three predictive models used to validate the proposed
framework: specifically, chapter 4 presents a model developed to predict
mortality within 28 days of patients suffering from acute alcoholic hepatitis [1],
chapter 5 describes the development of a predictive model to aid the diagnosis
of dementia [2], and chapter 6 presents the development of a model for
predicting and monitoring the side-effects in patients receiving chemotherapy
[3]. The development of such models also includes the implementation of web-
based CDSSs built on developed models and different attempts to improve
their performance.
Concluding remarks and ideas for future work are presented in chapter 7.
Appendix A presents an investigation on information and communication
technology usage in patients [4] (the author’s contribution is the statistical
data elaboration and the subsequent interpretation of results) and appendix B
describes the mathematical formulation of linear regression, logistic regression
and gradient descent.
1.2 motivation and aims
The increased demand for medical care (also due to the increase in average
life expectancy) and the need to keep health costs under control, makes the
exploration of new ways of delivering healthcare crucial.
1.3 original contributions 20
Clinical decision support systems (CDSSs) are able to aid in the acquisition of
patient data and to suggest appropriate decisions on the basis of the acquired
data. Literature has identified many improvements which are envisaged from
the adoption of such systems, including improved patient safety, better quality
of care and enhanced efficiency in healthcare delivery.
However, published studies have frequently not followed commonly recom-
mended procedures for model development and substantial shortcomings in
reporting results have been ascertained.
The first objective of this interdisciplinary work is to design a sound
framework for the development of clinical decision support systems. We
propose a framework supporting the proper development of such systems,
and in particular the underlying predictive models, identifying best practices
for each stage of the model’s development. Another main aim of this thesis is to
build some applications based on the proposed framework, able to outperform
state of the art models. As a peripheral objective, we also want to investigate
possible barriers to the delivery of CDSS to patients using information and
communication technologies (ICT).
1.3 original contributions
A schematic view of the original contributions of this thesis is hereby reported.
1.4 publications 21
1. Chapter 3: a framework supporting the proper development of clinical
decision support systems, and in particular the underlying predictive
models, is proposed.
2. Chapter 4: a new mortality risk model to identify patients suffering from
acute alcoholic hepatitis is developed, outperforming by 25% available
state of the art tools. [1]
3. Chapter 5: a predictive model to aid the early diagnosis of dementia
is developed, outperforming the considered benchmark by 15% and
providing an analysis of the variables significance. [2]
4. Chapter 6: a side-effect model for cancer patients receiving chemotherapy
is developed, showing the enhanced predictive power compared to the
previous models. [3]
1.4 publications
The following papers have resulted from the research presented in this thesis.
• T. Mazzocco and A. Hussain, "A side-effects mapping model in patients
with lung, colorectal and breast cancer receiving chemotherapy," in
13th IEEE International Conference on e-Health Networking Applications and
Services (Healthcom), pp. 34-39, IEEE, 2011.
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• T. Mazzocco and A. Hussain, "Novel logistic regression models to aid
the diagnosis of dementia," Expert Systems with Applications, vol. 39, no.
3, pp. 3356-3361, 2012.
• T. Gandiya, A. Dua, G. King, T. Mazzocco, A. Hussain, and S. J. Leslie,
"Self-reported ’communication technology’ usage in patients attending a
cardiology outpatient clinic in a remote regional hospital," Telemedicine
and e-Health, vol. 18, no. 3, pp. 219-224, 2012.
• T. Mazzocco, A. Hussain, S. Hussain, and A. A. Shah, "A novel mortality
model for acute alcoholic hepatitis including variables recorded after
admission to hospital," Computers in biology and medicine, vol. 44, pp.
132-135, 2014.
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S TAT E O F T H E A RT
This chapter introduces a general definition of a clinical decision support
system and an analysis of the motivations for the present work. The role
of existing medical knowledge in such systems and the way to extract new
knowledge using data mining techniques are then presented. Finally a review
of the features of effective clinical decision support systems and their envisaged
benefits in delivered clinical practice concludes the chapter.
2.1 clinical decision support systems
The idea of developing automated tools able to deal with the complexity of
clinical information processing dates back to at least 1969: a work by Goertzel
[5] highlighted the increasing need for better medical care due to the rapid
growth of medical knowledge and the shortage of physicians. This work
gave the definition of clinical decision support system (CDSS) as a "computer
program to aid in the acquisition of patient data and to suggest appropriate
decisions on the basis of the data thus acquired". So two main functions are
identified for a CDSS:
23
2.1 clinical decision support systems 24
• to help with data acquisition processes (clinical variables may include
boolean variables, numeric values and free text descriptions);
• to assist health professionals with decision making tasks (e.g. diagnosis,
suggested treatments, further examinations).
Almost 50 years later, the ideas behind clinical decision support systems are
still the same: the increased demand for medical care, also due to the increase
in average life expectancy, and the need to keep control of health costs make
the adoption of new ways to deliver healthcare crucial.
Many improvements are envisaged from the use of such systems including:
reduction of costs by faster diagnosis, reduction in unnecessary examinations,
reduction of the risk of adverse events and medication errors, increase in
available time for direct patient care, improved medication and examination
ordering, improved patient satisfaction, and application of gold-standard up-
to-date clinical pathways and guidelines. Potential benefits from CDSSs may
then be summarized in three areas [6]:
• improved patient safety;
• improved quality of care;
• improved efficiency in health care delivery.
CDSSs have the potential to meet these needs, and the huge amount of clinical
data which is collected and recorded nowadays seems to pave the way for a
radical change in medical practice.
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Nowadays a huge amount of information is collected in the healthcare
environment, which could still be defined as ‘information rich’ yet ‘knowledge
poor’. This is due to a lack of effective tools able to analyze and discover
underlying relationships and patterns in clinical data, while data mining and
knowledge discovery have found many applications in other scientific domains
[7].
Different studies have shown that, for different reasons, health care is
suboptimal. From a very general point of view it has been noted [8] that
while healthcare sectors require person-to-person interaction for treatment
assessment, diagnosis, planning and decision making, the delivered decision
support does not need such interaction. Information services in healthcare, and
specifically decision support systems, should consider the need for a much
greater degree of interpersonal communication compared to other sectors.
Also, healthcare information services should be modelled on a national scale,
in order to integrate data from different providers, while generally attempts
are made to build solutions for smaller units (e.g. hospital, surgery, clinic).
Another study [9] has shown that while overall differences between primary
care quality indicators in deprived and prosperous communities were small,
both clinical and non-clinical indicators suggested that there is scope for
focused interventions on healthcare delivery with a view to improving the
quality of primary care in deprived areas.
Evidence [10] has shown that practitioners do not always adhere to re-
commended clinical practice. However, compliance improves following a
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structured intervention, even if research studies do not indicate for how long
the intervention affects practitioner compliance: appropriate decision support
tools may help to increase practitioners’ compliance to recommended practice.
In fact, to improve the chance that a decision support system has a positive
influence, it has been found [11] that providing personalized feedback to
practitioners was effective in order to improve adherence to recommendations.
Also, requiring practitioners to acknowledge received reminders improved
their adherence to recommendations [12].
Due to the discrepancy between clinical care actually being delivered and
optimal patient care, alternative care models in traditional primary care are
being actively explored. Published studies of clinical decision support systems
(CDSSs) are increasing and their quality is also improving [13]: such systems
can enhance clinical performance for drug dosing and prescribing, preventative
care, diagnosis, disease management and other aspects of medical care.
Another research study [14] on the effects of computerized CDSSs on
practitioner performance concluded that such systems may improve prac-
titioner performance and identified few barriers to its implemetation in clinical
practice including: failure of physicians to use the system, poor integration into
practitioner workflow, poor usability of the tools, non-acceptance of computer
recommendations.
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2.2 the role of knowledge
An important categorization among clinical decision support systems can be
based on the "reasoning" engine of the system [15]: a knowledge-based CDSS is
a CDSS with a knowledge base that consists of compiled information (often
presented as a number of if-then rules) used to associate the input received
from the user with the output provided to the user.
Examples of such CDSS can be found online based on the well-known Fram-
ingham study dating back to 1976 for general cardiovascular risk prediction
[16]: this risk model used four boolean variables (sex, smoker, treatment for
hypertension, diabetes) and three numerical variables (age, blood pressure,
body mass index) to calculate a risk score of cardiovascular events.
Online tools collect necessary information from the user (and needed
explanations) and are able to provide an immediate answer; this could be
directed to healthcare professionals, who may consider the risk score as one
of the preliminary indicators of patient’s health condition, but also to the user
of the system who may be then guided to appropriate actions to improve their
health condition (e.g. modifying lifestyle) or redirected to general practitioners.
On the contrary, a non-knowledge-based CDSS do not rely on previous
knowledge and uses a number of data points to provide predictions on new
unseen cases. These rely on standard statistical and/or more sophisticated
machine learning algorithms in order to make the system learn from available
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clinical data, recognize patterns and improve predictions based on new
annotated data.
For example, a recent PhD thesis [17] from Computer Science and Artificial
Intelligence Laboratory (CSAIL) of Massachusetts Institute of Technology (MIT)
developed some logistic regression models to detect hazardous episodes for
patients in intensive care units. A number of real-time mortality models have
been developed exploiting data coming from the Multi-parameter Intelligent
Monitoring for Intensive Care (MIMIC) database, which was created to
facilitate the development and evaluation of intensive care units (ICU) decision-
support systems. Data have been pre-processed before developing predictive
models which have been subsequently validated.
At this point, it can be useful to note that non-knowledge-based CDSSs
can also be exploited to generate new clinical knowledge: the analysis of
the models obtained from clinical data suggests which factors may influence
positively or negatively the provided output (e.g. a diagnosis, an expected
side-effect, the necessity for further treatment).
It is then possible to identify a third role of a CDSS in the context of
scientific research (along with tasks related to helping in data acquisition
and decision making): in fact, to some extent, non-knowledge-based decision
support systems have the capacity to learn from available data, leading to the
identification of new relationships between provided input and desired output
and, ultimately, facilitating the creation of new clinical knowledge [18].
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Another recent example [19] of non-knowledge-based CDSS was developed
by collecting data from an integrated sensor network which was installed
in apartments for volunteer residents at a retirement community that allows
residents to remain in their apartments even if their health deteriorates. The
sensor networks supplement registered nurse care coordination by alerting
them of changes in the normal sensor patterns. The analysis of data collected
from such sensors (bed restlessness sensor, living room motion sensor, and
bathroom visits for each resident) led to the discovery of anomalous behaviors
which were strongly correlated to urinary tract infections. In this case, the
sensor network was able to detect signs of illness earlier than traditional
health care assessment. This example shows how heterogeneous and diverse
information collected in the healthcare environment may lead to discovering
hidden relationships with clinical conditions.
We can then design a CDSS which analyses a large amount of data, with a
view to discovering hidden (and possibly complex) patterns. Also, we can use
existing knowledge to design a CDSS, and then use a new set of observations
to show how to refine gold standard practice or to identify possible conflicts
with the existing knowledge base.
For the scope of this work, moving from available medical knowledge, we
focus on building new CDSSs with a view to improving gold standard practice
when possible, extracting also new information from available data.
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2.3 features of an effective system
Despite the huge number of developed CDSSs, only a few of them are then
integrated into clinical workflows. A recent study [20] has estimated that such
systems have improved clinical practice in about 68% of the considered cases.
It also identified features of computer based decision support systems which
significantly correlated with a positive impact on clinical practice:
• automatic provision of decision support as part of clinician workflow;
• provision of recommendations rather than just assessments;
• provision of decision support at the time and location of decision making.
Moreover, direct experimental evidence supported the importance of three
further system characteristics:
• providing periodic performance feedback;
• sharing recommendations with patients;
• requesting documentation of reasons for not following recommendations.
Another recent study [21] confirmed that systems that required practitioners
to provide reasons when overriding advice and, even more importantly,
systems that provided advice concurrently to patients and practitioners were
more likely to be effective in clinical practice.
Multiple studies have emphasized the importance of transparency in clinical
decision support systems: it has been highlighted that such systems must
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be implemented ensuring transparency so that the source and strength of
evidence are fully disclosed to clinicians and other decisionmakers [22].
An effective clinical decision support system should be able to evaluate
available patient data in real time, and to provide decision support (e.g.
prompts, reminders, and suggestions for management, patient-specific recom-
mendations) in a transparent way, so that suggestions can be easily linked to
the source of evidence [23].
There is a strong requirement that the decision support in key areas of
medication management and clinical care is provided in a way that allows
healthcare professional to determine its credibility and validity by means of a
transparent decision making process [24].
2.4 an overview of data mining
As previously discussed, the large growth of available medical databases has
motivated the use of data with a view to discovering new medical knowledge
from such databases. Data mining techniques could be employed to extract
new clinical knowledge and then to provide better diagnostic capabilities
and more effective patient care; potential uses of data mining techniques for
medical diagnostics have been ascertained [25]. Knowledge management in
the healthcare system is nowadays crucial in order to achieve high-quality
cost-effective services and data mining techniques may help to exploit the full
potential of collected data within an organization [26].
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A group of heterogeneous algorithms are described as data mining tech-
niques; they are used for different purposes but all with a view to discovering
the hidden knowledge in the data. Generally, the algorithms try to fit a model
which is the closest to the characteristics of the considered dataset, in order
to build predictive or descriptive models, where predictive models are used
to make predictions (e.g. to make a diagnosis for a specific disease) while
descriptive models are used to identify patterns in data. For the scope of this
thesis, we will focus on building predictive models.
The main data mining tasks were enumerated and described [27] as follow:
• Classification which classifies each data item into one of several predefined
classes. It is possible to derive a set of classification rules from the
classification model (based on the training dataset); this set of rules
represents the knowledge extracted from the used dataset and can be
used to classify unseen data items. This is probably the most important
data mining technique, as medical diagnosis is an important application
of classification.
• Regression is a method to map target data with a known type of function,
with the aim of estimating an output value given unseen input values.
• Time series analysis concerns the study of an attribute value examined
over a time period (generally at evenly spaced time intervals), with a
view to predicting future values of the attribute.
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• Visualization techniques are useful in order to discover hidden patterns
in the considered dataset. Through the analysis of scatter diagrams (in
a Cartesian plane) it is possible to identify interesting subsets of the
initial dataset: other data mining techniques can then be applied on these
subsets in order to discover further knowledge.
• Association rules is the discovery of rules which create associations among
objects.
• Clustering is a set of techniques of multivariate data analysis aimed
at the selecting and grouping of homogeneous elements in a dataset,
based on measures of similarity between the elements within a multi-
dimensional space. Common features of the objects in each cluster are
then summarized to extract the class description used to classify unseen
data points.
2.5 logistic regression models
Logistic regression is a widely used algorithm which frequently appears in
medical literature. It is a well established technique which is usable without
any specific machine learning skill; also, many software tools are readily
available to develop logistic regression models. It is a multivariable method
which tries to establish a functional relationship between two or more predictor
(independent) variables and one categorical outcome (dependent) variable in
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a transparent way: which leads to an easy interpretation of developed models
and may explain the broad diffusion of such technique. In logistic regression
the probability of Y occurring is predicted given known values of X (vector
containing predictors). The general form of the functional dependence given
by the regression could be expressed as per formula 2.1:
P(Y) = (1+ e−(b0+b1x1+·+bnxn))−1 (2.1)
where P(Y) is the probability of Y occurring (or, in other words, of Y
belonging to a certain class), xn are predictor variables and bn are coefficients
to be determined by the logistic regression algorithm. The coefficients are
estimated by fitting models, based on the available predictors to the observed
data. The chosen model will be the one that, when values of the predictor
variables are placed in it, results in values of Y being the closest to the observed
values.
Further details about logistic regression models and techniques used to
estimate coefficients will be provided in the following appendix B. Two
applications presented in this thesis will use logistic regression which is
one of the most used model for developing CDSSs.
2.6 pitfalls in published predictive models
A recent study [28] identified 10 criteria used to examine the quality of
published logistic regression models; specifically:
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• selection of independent variables: studies should explain how variables
were selected for inclusion in the model. They may be chosen based
on earlier research or in the presence of significant correlation with the
dependant variable
• coding of variables: studies should provide a complete description of the
coding scheme for independent variables (i.e. how they are recorded and
coded). The coefficient for an independent variable and the subsequent
interpretation strongly depend on such scheme which is crucial to the
future usability of the model
• sufficient events per independent variable: the ratio between the number
of events of the less frequent outcome and the number of model inde-
pendent variables should be at least 10 to 1. If the number of events per
independent variable is lower, the estimates of the regression coefficients
may be unreliable and the related sample variance, as well as confidence
intervals, may also be affected
• collinearity: studies should report results of undertaken tests for collin-
earity, i.e. should investigate whether two or more explanatory variables
have an approximate linear relationship between them: such conditions
may increase the variance of the coefficient estimates making them very
sensitive to minor changes in the model
• conformity with linear gradient for continuous variables: models with con-
tinuous or ranked independent variables should assure conformity with
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the linear gradient or check on the log-odds scale (this is not applicable
to boolean predictor variables), i.e. any given change in a continuous
predictor variable should have an effect on the log-odds of a positive
outcome that is the same magnitude, regardless of the value of the
predictor variable [29]
• statistical significance: statistical significance of each coefficient should be
investigated and results reported
• fitting procedure: the procedure for entering variables (e.g. forward or
backward selection) into the model should be explicitly stated
• tests for interactions: studies should include a discussion of reasons for
including or not interaction terms, i.e. variables obtained as functions of
two or more original predictors (e.g x1x2)
• validation: models should present used validation procedures (e.g. cross
validation, split-sample methods, bootstrapping) and discuss results: this
step is crucial in order to correctly estimate the accuracy of a classifier
• goodness-of-fit and discrimination measures: goodness-of-fit measures an-
d/or discrimination statistics (ROC curves) should be reported along
with a description on how well the developed model matches the
observed values
The study in [28] also provided an analysis which assessed a number of
published papers on two medical journals: they concluded that published
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Criterion % studies
Selection of independent variables 81%
Coding of variables 10%
Sufficient events per independent variable 40%
Collinearity 17%
Conformity with linear gradient for continuous variables 19%
Statistical significance 100%
Fitting procedure 65%
Tests for interactions 39%
Validation 9%
Goodness-of-fit and discrimination measures 19%
Table 2.1: Studies which satisfy criteria for quality of logistic regression models
studies frequently did not follow commonly recommended procedures for
using multivariable logistic regression. The results from this study is reported
in the table 2.1, which shows the percentage of considered studies which
satisfied the abovementioned criteria.
Another study [30] considered logistic regression models (which often find
privileged positions in literature reviews) in a specific medical domain, i.e.
genetic testing for cancer susceptibility. They found substantial shortcomings
in the use and reporting of logistic regression results. Notable results were
that no study reported any regression diagnostics or goodness-of-fit measures;
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none of the studies reported validation analysis; most of the considered
models had a ratio between events and independent variable near or below 10,
suggesting that those models may be unreliable. Also, in the genetic testing
for cancer susceptibility domain, published literature reviews have accepted
conclusions from analyzed studies, which did not address the appropriateness
and accuracy of the statistical analyses and other discussed methodological
issues. This could lead to possible design flaws in these models and, while the
conclusions of these studies may still be valid, once they are considered for
inclusion into counseling guidelines and testing protocols, they may produce
new clinical knowledge based on results that had not been rigorously tested
following recommended statistical guidelines.
2.7 towards a general framework
The analysis presented in this chapter shows the potential of CDSSs and, at the
same time, the criticalities found in the published literature highlighting the
need for a general framework able to exploit such potentials avoiding common
pitfalls. The idea developed within this thesis is then to design a flexible
framework able to cope with different kinds of healthcare data - depending
on application and performance requirements, required models can range
from simple to complex - and to build effective models to be implemented as
CDSSs.
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In the following chapters of this thesis, a general framework will be de-
veloped: some applications will be proposed, developing predictive models
and implementing at the same time (most of the) recommended practices
previously discussed. The main objective is to design a general framework
based on clinical and technological best practices, able to help researchers
in this multidisciplinary domain develop effective clinical decision support
systems.
3
F R A M E W O R K D E S C R I P T I O N
In the previous chapter, a number of pitfalls recurring in the published
literature for developing CDSSs have been highlighted. There is then a need
for a general framework able to exploit the potential of medical data avoiding
common pitfalls which have been discussed in the previous section 2.6.
In this chapter, a framework for developing CDSSs, and in particular the
underlying predictive models, is proposed: this will be able to deal with some
of the most widely used kind of healthcare data and will help researchers to
develop effective CDSSs.
Section 3.1 describes how to prepare the dataset which will be used for the
model construction, which is detailed in section 3.2. A methodology to evaluate
model performance is defined in section 3.3 and appropriate performance
metrics for two-class classification problems are described in section 3.4.
Then, section 3.5 illustrates how to analyze model misclassifications, i.e.
cases in which the classification proposed by the system differs from the real
classification, and section 3.6 closes the chapter suggesting how to implement
the model into an actual CDSS software application.
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3.1 dataset preparation
As previously mentioned, a non-knowledge-based CDSS uses a known dataset
to provide predictions on new unseen cases. The dataset is composed of a
number of data points: each of them has a number of inputs expressed as
independent variables (i.e. variables used to make predictions) and one output as
the dependent variable (i.e. the associated outcome). This section examines how
to pre-process the dataset in order to properly feed the learning algorithm
used for model development.
3.1.1 Variables pre-processing
When developing a new model, a number of candidate variables are available:
their collection is generally driven by previous research and/or by the expertise
of domain specialists. Also, in the absence of such indications, the presence of
a significant correlation with the dependent variable could be investigated by
means of appropriate statistical tests.
Variables can be categorized into:
• continuous variables, which can assume any real value within given
intervals;
• categorical variables, which can assume a finite number of values.
Categorical variables can be further classified into:
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• binary variables, which can assume only two values;
• nominal variables, which can assume a finite number of values without an
intrinsic order;
• ordinal variables, which can assume a finite number of values with an
intrinsic order or ranking.
Continuous variables are normally used “as is” or after a normalization
process, which consists in a transformation R → [0, 1] or R → [−1, 1] of the
variable domain. Different methods are available for such transformations
(e.g. min-max normalization, z-score normalization) and many artificial neural
networks and classifiers based on distances require a normalization step
in order to give consistent results [31]. While not necessary, this process is
sometimes applied to regression and logistic regression as well (e.g. when
the same dataset is also used with other techniques requiring normalization).
In this case, it is crucial that the function used for normalization is explicitly
reported when the model is described in order to consistently apply input
normalization when the model is used.
Categorical variables cannot be used “as is”. They need to be coded into
a series of n− 1 binary variables where n is the number of categories to be
represented: it has to be noted that n− 1 binary variables are able to define
exactly n categories, while using n binary variables would lead to a n-th
variable which could be expressed as function of the other n− 1 ones causing
problems to learning algorithms (i.e. making impossible the matrix inversion in
the estimation algorithm), making the regression problem unsolvable [32]. This
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coding is necessary to avoid the well known “dummy variable trap” which
is special case of exact multicollinearity: if there is no omitted category, there
is an exact linear relationship between the model constant and the dummy
(binary) variables [33].
Generally speaking, model specifications should always explain how vari-
ables are collected (including units of measure), calculated and used in order
to guarantee that the model will always be applied to datasets which are
consistent with the one used for developing such models, i.e. variables are of
the same kind and measured in the same unit.
3.1.2 Collinearity among independent variables
A preliminary test of collinearity should investigate whether two or more
independent variables have a strong correlation: if there is perfect collinearity
between independent variables it becomes impossible to obtain unique estim-
ates of the model coefficients [34]. However, also high levels of collinearity
present a problem for any regression analysis [35], increasing the probability
that a good predictor (i.e. an independent variable which has good explanatory
power) is considered not significant and then rejected by the model.
As already discussed, it is estimated that less than 20% of published
literature on medical logistic regression models reported appropriate tests for
detecting collinearity problems. The methodology proposed in this framework
requires that an appropriate test is carried out to detect collinearity situations.
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Various collinearity diagnostics are available: for example, the variance infla-
tion factor (VIF) or the tolerance statistics (defined as 1/VIF). VIF provides an
estimate of how much the variance of an estimated coefficient is increased by
the effect of collinearity [36]. Common criteria to determine if a collinearity
problem is present are a tolerance value less than 0.1 [37] or, equivalently, a
VIF value greater than 10 [38].
3.1.3 Variables selection
Stepwise regression is a procedure to select which variables should be included
in a regression model. The idea is to build a model with a specified number
of variables and then add (or remove) them one by one, according to a
specified ranking, and then check whether the model significantly improved
(or deteriorated) its performance. Such an iterative procedure terminates when
adding (or removing) variables does not improve (or does deteriorate) the
model accuracy.
Two approaches may be followed: backward stepwise elimination, which
starts with all candidate variables and at each step one variable is removed
evaluating if performance deteriorates, and forward stepwise selection, which
starts with no candidate variables and at each step one variable is added
evaluating if performance improves [39].
For the framework proposed in this thesis, the backward method is preferred
because forward selection is more likely than backward elimination to exclude
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independent variables involved in suppressor effects [34] (i.e. variables which
increase the predictive power of other independent variables by their inclusion
in a regression equation [40]). Forward selection may be used in an attempt to
reduce computational time, if techniques involved in model construction are
computationally heavy and/or the used dataset is big enough.
The implementation of variables selection strategies can lead to increased
model performance, as will be shown in sections 4.5 and 5.5.
Stepwise regression suggests the best set of variables to fit points in a
specified dataset according to a certain functional form. However, the number
of variables which can be used in a model is limited by the size of the dataset
used to estimate coefficients: introducing more variables will generally produce
a better fit to the data but an excessive number of variables may overfit the
dataset, leading the model to lose its generalisation power.
In order to create a model able to show similar accuracy on an unseen
dataset, a dataset of adequate size, which could provide reasonably accurate
estimates of the regression coefficients, is necessary.
If too many degrees of freedom are used, i.e. if too many coefficients are
estimated with respect to the number of data points contained in the dataset,
the resulting model will overfit the considered sample: it will include predictor
variables and identify complex relations between input and output of the
model that exist in the considered sample (leading to an overestimation of
model accuracy) but not in the population, and this is detrimental to the real
accuracy of the model. In the case of regression models, if the number of
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the coefficients to be estimated is equal to the number of data points on the
considered sample, the model may perfectly fit the sample data, even if all the
predictors are totally unrelated to the response variable (i.e. they are noise)
[41].
Summing up, although it is important that the model includes all relevant
variables, it is also important that the model does not start with more variables
than those that are justified for the given number of observations [29, 42, 43].
Given a specific dataset, for logistic regression it is recommended that the
ratio between the minimum number of data points belonging to a class and
the number of independent variables used for the model should be at least 10
[44]: if such criterion is not met, results should be taken with care and a larger
dataset should be used to strengthen findings. This rule will help selecting the
appropriate set of independent variables as in the first case study described in
paragraph 4.4.2.
3.2 model construction
After dataset preparation, a number of data points are available for the model
construction phase.
The vector of selected candidate independent variables is called X and B is
a vector of coefficients. The aims of the step described in this section are 1)
to find a function yˆ = f(B,X) able to approximate the real relationship y(X)
between X and the dependent variable y and 2) to determine vector B.
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The first element of the vector X is set to x0 = 1, in order to include in the
developed models a possible constant term while keeping a compact notation.
The form of function f is based on the available knowledge about the
relationship between the model input and output. Also, continuous variables
can be used stand-alone or as arguments in functions of one (e.g. sin x1) or
more variables (e.g. x1x2), again based on the available knowledge about the
problem. An appropriate usage of a priori knowledge will result in more
accurate models as highlighted in paragraph 6.4.1.
3.2.1 Regression
Depending on desired output y, in most cases, linear and logistic regression are
able to provide models with a reasonable level of accuracy. These techniques
will be used in the following chapter 4 and 5 (logistic regression), and 6 (linear
regression).
In particular, if y ∈ R, linear regression could be used. Otherwise, con-
sidering classification problems (i.e. y ∈ {0, 1}), logistic regression should be
selected; in this case, the model output yˆ = f(B,X) is the probability of an
input data point belonging to a certain class. A threshold is generally applied
to the probability calculated from the model in order to predict the class
to which the data point is expected to belong. Besides being needed in the
practical usage of the model, the threshold is also commonly used to quickly
evaluate the accuracy of the model (i.e. once a threshold has been chosen, the
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accuracy is easily evaluated as described in the following section 3.4). However,
the predictive power should be evaluated regardless of an arbitrarily chosen
threshold using receiver-operating characteristic (ROC) curves, as detailed
hereinafter.
A linear regression model will assume the form:
f(B,X) = b0 + b1x1 + b2x2 · · ·+ bnxn = BTX (3.1)









After having defined the functional form of the model, an algorithm is
necessary to determine the coefficients vector B. Generally, this is estimated in
the training phase of the model minimising an opportune cost function J(B)
defined for the problem.
It is worth noticing that the most commonly used cost functions tend to fit
data points, without weighting differently false positives and false negatives
which could have different costs. For the scope of this thesis, this is acceptable
as an investigation about costs of false positives and false negatives was
not available. However, it is recommended that cost functions are, whenever
possible, modified in order to take care of such cost differences.
Appendix B provides further details of mathematical formulation of linear
and logistic regression, including commonly used cost functions, as well as a
description of a gradient descent algorithm which could generally be applied
to minimise cost functions.
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A statistical p-value is associated to any coefficient of linear and logistic
regression. For each coefficient, the p-value tests the null hypothesis that the
coefficient is equal to zero (i.e. it has no effect on the model).
Importantly, it is required that the p-value should be clearly reported for
every coefficient. A low p-value (e.g. smaller than 0.05) indicates that the null
hypothesis can be rejected (i.e. a predictor with a low p-value is likely to be a
meaningful addition to the model because changes in the predictor’s value are
related to changes in the response variable), while a larger p-value implies that
changes in the independent variable are not associated with changes in the
output. Such p-values are used as ranking criterion in the stepwise regression
procedure described in the previous paragraph 3.1.3.
Also, in a linear regression, the coefficient of determination (or R2) is the
proportion of variability in a data set that is accounted for by the statistical
model and it varies between 0 and 1. So, the higher is the R2, the better is the
goodness of fit. There is not a unique definition of R2 coefficient for logistic
regression models. It is then suggested that coefficients of determination are
reported at least for linear regression models.
The general procedure described in this section could be generalized to some
other techniques, taking care of adapting functional forms, cost functions and
minimisation algorithms as appropriate. Adopted functional form, coefficients
and possibly cost function (if not standard) should always be clearly reported
on research studies detailing developed models.
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3.3 model validation
The aim of a classification task is to associate each element of a dataset to a
class amongst a number of possible ones. Regression and logistic regression
algorithms (as well as other supervised machine learning techniques) infer a
model from labeled training data. The generated model is then evaluated on a
separate testing set, which provides an estimate of the accuracy of the model.
A correct estimation of the accuracy of a classifier (in this context, also
referred to as model validation) is crucial both to predict its future predictive
power and to choose among a number of possible classifiers.
Despite the importance of correctly determining the accuracy of a model,
as previously outlined in section 2.6, it is estimated that more than 90% of
medical logistic regression models among published literature do not use an
appropriate model validation strategy.
In order to correctly assess the accuracy of a classifier, an estimation method
with low bias (i.e. the difference between real and estimated accuracy) and
low variance (i.e. the variability of estimated accuracy when changing the
used dataset) is desirable [45] and required by the framework proposed in
this work. Three methods are recalled to estimate predictive power of a model:
holdout, bootstrap and cross-validation methods.
The holdout method divides the available dataset into two partitions, the
training and the testing set: the first one is used to build the model and the
second one to evaluate its accuracy.
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The bootstrap method [46] creates, given a dataset of size n, a number of
testing sets by sampling n instances uniformly from data with replacements,
i.e. some of the data points will appear in the bootstrap sample multiple times
while other data points will not appear at all. Called p the probability of
any given instance being chosen after n samples, b the number of bootstrap
samples, αi the accuracy computed on the i-th sample, and a the accuracy
computed on the whole training set, the accuracy estimate can be expressed
as 1b
∑
i p ·αi + (1− p) · a. The variance of the estimate is calculated as the
variance of the accuracy estimates for the samples.
The k-fold cross-validation method divides the available dataset into k parti-
tions of similar sizes. A model is built k times, using each time k-1 partitions as
the training set and the remaining partition as the testing set. The estimation of
the accuracy model is the average of the accuracies computed for the developed
k models. If a dataset is composed of n data points, the n-fold cross-validation
is also know as leave-one-out cross-validation. Cross-validation is defined
as “stratified” if each partition reflects the distribution among classes of the
original dataset.
A largescale experiment on real-world datasets [45] (following experimental
results on artificial data and theoretical results in restricted settings) and a
recent simulation study [47] compared the performance of these validation
methods showing that:
• holdout will generally underestimate the accuracy of the model, hence
inducing a large bias, because only a portion of data is available for the
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learning process (since the accuracy of a model deriving from supervised
learning algorithms increases when more data points are presented
during training); on the other hand, using a test set with fewer data
points will largely increase the variance of the accuracy estimation
• bootstrap has low variance, however, it may present an extremely large
bias problem for both some large and small samples.
• cross-validation provides decreasing bias accuracy estimation while
increasing k, reaching a virtually unbiased estimation with the leave-one-
out cross-validation where almost all data points are used for training
purposes; as k decreases, the accuracy variance increases due to the
instability of the used training sets. When compared to regular cross-
validation, stratification is generally a better scheme, both in terms of
bias and variance
Based on such observations, for the framework hereby developed, stratified
cross-validation is proposed for model selection and accuracy estimation due
to its lower bias when compared to other proposed methods.
3.4 model evaluation
CDSSs are often based on binary classification models, that is their aim is to
classify each entry of a given dataset into two groups, positives and negatives,
according to a classification rule. In the clinical domain, the choice of what to
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define as positives and negatives is normally not arbitrary: a positive generally
indicates an anomalous condition which needs to be addressed, such as the
presence of a disease. As a consequence, the cost of missing a positive is
generally higher than the cost of wrongly classifying a negative as a positive.
When the outcome of a model is the probability of an entry belonging to
a group, such probabilities need to be converted into a boolean value using
an appropriate threshold, in order to carry out the classification task. The
performance of the developed CDSS models can then be evaluated; for such
models, for each element of the dataset there are four possible outcomes with
regard to the classification:
• true positive (TP): when a positive is correctly classified
• true negative (TN): when a negative is correctly classified
• false positive (FP), also known as type I error: when a negative is wrongly
classified as positive
• false negative (FN), also known as type II error: when a positive is
wrongly classified as negative
Different measurements of model performance can be subsequently defined.
Given P = TP+ FN the number of real positives in the considered dataset, and
N = TN+ FP the number of real negatives, it is possible to define [48]:
• sensitivity = true positive rate (TPR) = recall = TP/P
• specificity = true negative rate (TNR) = TN/N
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• positive predictive value (PPV) = precision = TP/(TP+ FP)
• negative predictive value (NPV) = TN/(TN+ FN)
• accuracy = (TP+ TN)/(P+N)
Such performance measurements are often used in literature. However,
they do not properly and satisfactorily characterise the predictive power of a
classifier. Indeed, false positive and false negative could have different kinds
of implications in different domains, clear examples of which are shown in
[49, 50, 51]. As a consequence, the decision threshold used to separate positive
and negative outcomes is dependent on the assumed costs for type I and II
errors, i.e. false positives and false negatives, and may vary depending on the
acceptable trade-off between false positives and false negatives.
However, the predictive power of a model should be evaluated regardless
of the chosen cut-off point. For this reason, receiver-operating characteristic
(ROC) curves have been adopted for the framework proposed in this work
as they provide an index of accuracy by determining the model’s ability to
discriminate between alternative states of health over the complete spectrum
of operating conditions, i.e. different thresholds [52]. A ROC curve can also be
thought as a plot of the probability of correctly classifying the positive cases
against the rate of incorrectly classifying true negative ones: in other words,
for each possible value of the decision threshold, a pair of true-positive and
false-positive performance rates are represented on the ROC curve.
In figure 3.1, the diagonal line represents the ROC curve of a random
classifier, the angular line shows the performance of an ideal classifier, and the
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Figure 3.1: Examples of ROC curves
other line corresponds to an example of the ROC curve for an example model.
The more the ROC curve tends to be near to the upper left corner, the better
the performance is: the area under curve (AUC) is used as a performance
metric and it usually varies from 0.5 for a random classifier to 1.0 for an ideal
classifier (i.e. 100% of true positive and no false negative are detected).
As previously outlined [28], less than 20% among analyzed studies reported
ROC curve analysis (i.e. used area under ROC curve as performance metrics).
Summing up, for classification problems, ROC analysis should always be
reported while further performance metrics could be reported if comparison
with previous work requires so.
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3.5 misclassification analysis
So far, some steps to assist the correct construction of a model have been
identified: firstly, clinical information is used to identify relevant variables and
hypothesize a model functional form; then the available dataset is used to
select variables to be included in the model, to calculate coefficients for the
model and to validate and evaluate the model itself.
Once that the model is developed, an output (e.g. a risk score, a classification,
etc.) can be associated to any previously unseen data point. When using
regression methods, this approach is completely transparent: indeed, it is quite
easy to identify positive/negative correlations, and their magnitude, between
each input of the model and the related output.
However, for classification problems, analyzing how misclassifications are
distributed may suggest some insight into the predictive power of the model:
it is sometimes possible to identify areas of input/output domains where the
model could be unreliable. In this case, different strategies could be adopted:
1) a pre-clustering may be attempted in order to build different models for
different areas of input domain; 2) where the model is not accurate enough,
the transparency constraint could be relaxed in order to apply a “black-box”
model, resulting in a model with improved performance while still reasonably
transparent; 3) leaving the classification of such data points to a domain expert
is also a possible choice, with the idea of using a decision support system only
when it could guarantee reasonable accuracy.
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The schematic representation of the proposed process for the model’s
development is reported in figure 3.2: available data and previous clinical
knowledge are used for selecting variables and for building (regression)
models; the dataset is then used to calculate the accuracy of the model and
to identify areas of low accuracy and different strategies may be used to deal















Black box models 
 
Figure 3.2: Schematic representation of the model building process
For the applications proposed in the following chapter 4 and 5, misclassific-
ation analysis is carried out. Because of the relatively small dataset sizes, areas
with high misclassification rate will be highlighted, suggesting that such areas
are dealt by domain experts.
The framework proposed in this thesis requires that an analysis of misclas-
sification distribution is always carried out, at least when the output of the
model is categorical: as will be shown in sections 4.6 and 5.6, such analysis
could lead to increased accuracy (not providing predictions for a number of
cases) selecting also cases (patients) where specialist prediction is needed.
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3.6 implementation
As previously highlighted, in order to have a positive impact on clinical
practice, a CDSS should automatically provide decision support as part of
a clinician’s workflow at the time and location of decision making. This
objective is reached implementing the model into a piece of software or a web
application.
The implementation of the model could also be used to collect new data for
further research work and/or to be used with an online training algorithm to
improve performance of existing models.
The applications proposed in the next chapters have been developed as
web-based prototype composed by PHP scripts, able to acquire data input
from users and generate an HTML page containing the related output.
4
C A S E S T U D Y 1 : A 28 - D AY M O RTA L I T Y M O D E L F O R
A C U T E A L C O H O L I C H E PAT I T I S
This chapter describes the first developed predictive model: its aim is to predict
mortality within 28 days of patients suffering from acute alcoholic hepatitis.
Severe forms of alcoholic hepatitis in patients with alcoholic liver disease are
in fact associated with high mortality; it is therefore vital to identify those
patients at greatest risk of mortality in 28 days as they may benefit from
aggressive intervention. Applying the previously described framework, we
propose a new predictive model that can be used in clinical practice to identify
such patients and to monitor their progress while in hospital.
A cohort of 82 patients was selected and for each of them, a number of
clinical findings and standard laboratory tests at the time of admission to
hospital were recorded. Variables from currently used scoring systems are
collected and, since studies have shown the usefulness of repeating scoring
systems after one week of admission to predict outcome, some variables were
collected up to 7 days after admission. It is expected that an appropriate
variable selection approach could lead to a better accuracy of the developed




The proposed logistic regression model selected four statistically significant
predictors (namely, the level of creatinine on and after admission, the pres-
ence of encephalopathy and prothrombin time evaluated after admission). A
comparison with the available mortality predictive scores showed an increase
by 25% in predictive power, demonstrating increased accuracy in identifying
these sick patients with alcoholic hepatitis in clinical practice.
4.1 background
Severe forms of alcoholic hepatitis (AH) in patients with alcoholic liver disease
(ALD), characterized by jaundice, hepatocellular damage and fibrosis [53], are
associated with high mortality especially in a younger population, but is also
frequent in older people, who are more susceptible to the effects of excessive
alcohol consumption [54]. It is estimated that severe alcoholic hepatitis has a
death rate of up to 50% [55]: therefore, it is vital to be able to identify patients
at greatest risk of mortality and in whom the therapeutic benefit/risk ratio is
unfavorable as this group of patients may benefit from aggressive intervention.
Multiple prognostic factors have been studied over the last decade and a
variety of scoring systems are used in clinical practice to assess the severity of
acute AH. They include, Maddrey Discriminant Function (mDF) [56], Child-
Pugh Score (CPS) [57, 58], Glasgow Alcoholic Hepatitis Score (GAHS) [59]
and Model for End Stage Liver Disease (MELD) [60]. A recent study [61] has
compared various prognostic scores used to evaluate the short-term mortality
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in patients with acute-on-chronic liver failure. In these scoring systems a
combination of various laboratory and clinical parameters are analyzed to
determine the severity of AH in patients with ALD. The mDF was derived
from observations of 55 patients: a stepwise discriminant analysis revealed a
statistically significant association with death of prolongation of prothrombin
time and height of serum bilirubin on admission to hospital. In the CPS, five
variables (namely: bilirubin, serum albumin, prothrombin time, presence of
encephalopathy and ascites) are used to predict the prognosis of chronic liver
disease.
The GAHS was built using a stepwise logistic regression algorithm and was
derived from few variables which were significant in respect of the patient’s
death risk: namely, age, serum bilirubin, and blood urea to predict 28-day
mortality risk, and serum bilirubin, prothrombin time, and peripheral blood
white blood cell count to predict 84-day mortality risk. Variables for the first
model (28-day mortality) were observed on day 1, while for the second one
(84-day mortality) they were measured on day 6-9.
In addition, various studies have suggested that a few individual parameters
such as elevated serum bilirubin level, international normalized ratio of
prothrombin time, white cell count and hepatic encephalopathy are associated
with increased risk of mortality in patients with AH [62, 63].
Predictive factors of long-term survival in ALD have recently been studied
[64]: only clinical factors were statistically significant prognostic factors while
no histological features correlated with prognosis. Non-invasive methods are
4.2 aims 62
also increasingly used to predict the prognosis of patients with chronic viral
hepatitis, reducing the need for liver biopsy analysis and facilitating the better
management of such patients [65].
A previous study [66] has shown that an increase of MELD score in the
first week is an independent predictor of mortality. Consequently, the present
study also considers the values of some selected variables evaluated days after
admission to hospital, i.e. bilirubin, urea, creatinine and prothrombin time,
were assessed also on following days up to day 7 after admission or to the
time of death if it occurs within 7 days, and included in the pool of variables
available for the model.
4.2 aims
The aims of this study are to propose a new enhanced predictive model which
could increase the accuracy of the currently available tools, identify individual
parameters that are associated with increased mortality and to assess if changes
in the values of these variables after treatment were associated with bad
prognosis in patients with AH. It is clinically crucial to identify patients with
severe AH by using these individual parameters so that their treatment can
be commenced and possibly adjusted early to reduce mortality. Moreover,
the possible introduction of variables - re-evaluated days after admission to
hospital - provides a way to constantly monitor the efficacy of administered
treatments.
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4.3 dataset preparation
4.3.1 Study sample
Patients with AH admitted to Crosshouse Hospital, Kilmarnock (UK) between
April 2003 and July 2008 were retrospectively analyzed. The diagnosis of
chronic ALD was made on the basis of a history of excessive intake of alcohol
over a period of several years and by the exclusion of other causes of chronic
liver disease either by blood tests or liver biopsy. In addition, the diagnosis
of acute AH in these patients was made by the presence of one or more
complications of chronic liver disease such as sepsis, upper gastro-intestinal
bleeding, encephalopathy, hepato-renal syndrome and serum bilirubin level of
more than 80 µmoles/L on admission.
Patients were excluded if they had evidence of co-existing viral hepatitis,
auto-immune hepatitis, hepatocellular carcinoma or biliary obstruction. In
addition, patients who died within 28 days of admission due to non-hepatic
complications were also excluded from the study. The final dataset has 82
patients: 45 patients were still alive after 28 days of admission, while the
remaining 37 patients succumbed to various complications of chronic liver
disease. The study was approved by Clinical Effectiveness Department of
Crosshouse Hospital, Kilmarnock (UK).
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4.3.2 Candidate variables
For each patient, a number of clinical findings and standard laboratory tests
at the time of admission were recorded, specifically:
• the age at acute diagnosis (expressed in years)
• aspartate aminotransferase (expressed in unit/L)
• alanine aminotransferase (expressed in unit/L)
• alkaline phosphate (expressed in unit/L)
• bilirubin and creatinine (expressed in µmoles/L)
• albumin (expressed in g/L)
• prothrombin time (expressed in seconds)
• white cell count (expressed in billion/L)
• urea (expressed in millimoles/L)
A number of binary variables were also collected:
• gender of patient
• presence of sepsis
• presence of encephalopathy
• presence of upper gastrointestinal bleeding
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In addition, serum bilirubin level, urea, creatinine and prothrombin time were
recorded on day 7 of admission or at the time of death if a patient died within
7 days. Patients were graded according to mDF, CPS, GAHS at the time of
admission.
Collinearity diagnostics have been run by means of the appropriate function
of PASW Statistic (SPSS), returning tolerance and VIF values: criteria described




For the purposes of this study, a logistic regression model was developed
including variables selected with a backward selection algorithm among all
the available ones (as detailed in the next paragraph 4.4.2); the performance
of this model has been compared with the available mDF, CPS and GAHS
models, which were evaluated on admission.
4.4.2 Variables selection and model validation
As discussed in paragraph 3.1.3, including extra variables in a predictive
model should, in principle, increase the accuracy of the model itself (or, at
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least, not decrease it). However, since we are building a predictive model
based on a limited sample, by adding more variables, we face the risk of
overfitting the dataset, posing some serious limitation to the scalability and
the generalization ability of the model (i.e. performance will be sensibly lower
using a bigger/different dataset). To overcome this problem, we have used a
backward stepwise algorithm, as prescribed by the proposed framework.
We have then evaluated the accuracy (based on a threshold of 0.5) of logistic
regression models using a 10-fold cross validation strategy, starting from a
model including all considered variables and ending with a model with a
single predictor. The number of variables to be considered for our final model
corresponds to the case with the best accuracy. Also, should the best accuracy
be reached in models with different number of variables, the one with the
smallest number of variables will be considered, assuming that collecting less
variables provides a more time and cost efficient approach.
4.4.3 Model evaluation
To quantify the performance of the proposed model compared to state-
of-the-art models, such as mDF, CPS and GAHS, the Receiver Operating
Characteristic (ROC) curves were used (evaluating the underlying area), which
compare the specificity and sensitivity of a model without regard to the chosen
threshold used to discriminate predicted outcomes [52].
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Number of variables 
Comparison of accuracies 
No validation 10-fold c.v. 
Figure 4.1: Comparison of accuracies with/without validation strategy
4.5 results
A logistic regression model was developed starting from all available variables,
also including the ones recorded at day 7 (or at death if this occurs before
day 7). We used a backward stepwise logistic regression algorithm to evaluate
the optimal number of variables given the used dataset in order to avoid
overfitting. The performance of each model, comprising a different number
of variables, has been reported in the following figure 4.1, comparing the
accuracy calculated using the whole dataset, and the accuracy implementing a
10-fold cross validation strategy.
From the analysis of the graph, while the best accuracy of the model with no
validation strategy is reached when considering at least 10 variables, the best
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accuracy of the model using a 10-fold cross validation approach is reached by
including 4 variables in the model (the same accuracy is reached also including
7 and 11 variables, however it is believed that a model with fewer variables is
cheaper to implement).
Then, our final model included four significant variables: namely, the level
of creatinine on admission (CR) as well as after admission (CR7), the presence
of encephalopathy (ENC, dummy variable) and prothrombin time evaluated
after admission (PT7).
The resulting model is reported in the following formula 4.1 where the score,
between 0 and 100, predicts the probability of mortality at day 28.
SCORE = 100 · (1+ e−M)−1 (4.1)
where
M = 0.046 ·CR7− 0.022 ·CR+ 0.159 · PT7+ 1.390 · ENC− 6.303 (4.2)
A detailed analysis of the model coefficients is provided in table 4.1, where
for each significant variable the coefficient, the standard error and the p-value
deriving from logistic regression are tabulated.
A comparison of the different scoring systems based on variables collected
on admission is tabulated on table 4.2: the performance of the three scoring
systems as well as our proposed predictive model in these patients was
individually analyzed using Student’s t-test, to check if a significant difference
exists between the average score for patients who died and patients who
survived (low p-values confirm this hypothesis), and by ROC curve analysis
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variable coefficient std. error p value
CR -0.022 0.010 0.033
CR7 0.046 0.013 <0.001
PT7 0.159 0.070 0.023
ENC 1.390 0.670 0.038
Constant -6.303 1.630 <0.001
Table 4.1: Analysis of coefficients from logistic regression model
to evaluate the global predictive power (measured by area under ROC curve,
indicated as AUC) of each model.
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Alive after Died within
Scoring system 28 days (n=45) 28 days (n=37) p-value AUC
mDF 37.2± 26.2 67.5± 56.9 <0.01 0.705
CPS 10.8± 1.6 11.8± 1.4 <0.01 0.681
GAHS 7.6± 1.6 8.7± 1.6 <0.01 0.687
Proposed model 24.5± 23.7 70.3± 30.7 <0.001 0.873
Table 4.2: Comparison of scoring systems in patients with AH, who died and survived
4.6 misclassification analysis
The objective of this section is to determine whether the model could be
unreliable under certain conditions. We carry out an a posteriori analysis of
how misclassifications are distributed along a specified domain: in our case,
we choose to study the distributions of predictions and misclassification as a
function of the model output. Operatively, the entire range of outputs has been
divided into 10 categories uniformely distributed between the minimum and
maximum values of obtained output values: considering SCORE (as defined
per formula 4.1) as model output, the interval to be divided into 10 categories
is [0, 1]; considering M (as defined per formula 4.2) we focus on the interval
identified by the extreme model output given using the considered dataset.
For this analysis we have chosen a representative threshold of 0.5.
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interval min 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
interval max 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
% misclassifications 3.3 16.7 0.0 0.0 50.0 66.7 0.0 14.3 0.0 5.0
Table 4.3: Distribution of misclassifications (function of SCORE/100)
interval min -11.5 -9.0 -6.5 -3.9 -1.4 1.1 3.7 6.2 8.7 11.3
interval max -9.0 -6.5 -3.9 -1.4 1.1 3.7 6.2 8.7 11.3 13.8
% misclassif. 4.5 0.0 14.3 50.0 9.1 0.0 50.0 0.0 0.0 0.0
Table 4.4: Distribution of misclassifications (function of M)
From the analysis of figure 4.2, it is clear that model predictions are
concentrated in the first (close to 0) and last (close to 1) selected intervals; also,
the proportion of misclassifications in such intervals are quite low as shown
in table 4.3.
On the other hand, we note that there is a region (approximately between
0.4 and 0.6) where the ratio between misclassification and total predictions is
greater than 50% suggesting that the developed model is not reliable at such
an interval of output.
The same results are shown on figure 4.3 and the related table 4.4, where
misclassifications are concentrated mainly at interval [−3.92,−1.39]. Excluding
such interval (where 11% of predictions are concentrated), and assuming a
threshold of 0.5, the accuracy increases from 88.7% to 93.7%.






































































Figure 4.3: Distribution of predictions and misclassifications (function of M)
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This information may be used to refine the model: for example, it is possible
to design and consider the output of a “second step” model if the output of
our proposed model is in the identified areas. Given the size of our dataset, we
prefer at this stage to simply warn the user that the model could be unrealiable
when the output is in such an interval.
For comparison purposes, the analysis of misclassifications distribution has
been carried out also for mDF model: the entire range of outputs has been
divided into 10 categories distributed between the minimum and maximum
values of obtained output values. Since only 3 data points had an output in the
second half of the selected interval, they have been considered “outliers” and
grouped in the tenth category. For this analysis we have chosen a threshold of
32 (giving an overall accuracy of 63.4%, close to the maximum attainable
accuracy of 64.6% using a different threshold), as suggested by relevant
literature [67]. Results are reported on figure 4.4 and on table 4.5.
Unlike the previous case, from the analysis of misclassifications it is not
possible to isolate a single area in the output space where accuracy is definitely
lower than the overall accuracy: a score between 32.8 and 74.5 (where 34%
of predictions are concentrated) suggests that the model can be unreliable.
Excluding such interval, the accuracy increases to 72.2%.
The comparison between mDF and the proposed model confirms that
misclassification analysis has the potential to increase the performances of
































Figure 4.4: Distribution of predictions and misclassifications for mDF
interval min 5.0 18.9 32.8 46.7 60.6 74.5 88.4 102.3 116.2 130.1
interval max 18.9 32.8 46.7 60.6 74.5 88.4 102.3 116.2 130.1 295.9
% misclassif. 21.4 34.8 46.2 60.0 60.0 20.0 28.6 n/a 50.0 0.0
Table 4.5: Distribution of misclassifications for mDF
reduce misclassifications are dependent on the considered model and possibly
on the used dataset.
4.7 implementation
The developed model has been delivered as web-based prototype. The core
of the developed prototype is a PHP script, which generates an HTML page
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after data is collected from a HTML input form and then POSTed when user
presses the "Calculate score" button.
This prototype, available at http://bit.ly/ald-calc, implements the mor-
tality model for acute alcoholic hepatitis developed in the previous sections of
this chapter, called Stirling ALD mortality predictor (SAMP). It is intended to be
used after 7 days from admission in hospital.
The user is asked to insert the level of creatinine at admission (CR) and on
7th day (CR7) in micromoles per litre, the prothrombin time (PT ) in seconds
and the presence of encephalopathy (ENC). The user interface is reported in
figure 4.5.
The SAMP score is calculated using formula 4.2, and probability of mortality
after 28 days from admission is computed by formula 4.1. An equivalence
between score and probability is reported for specified significant values. An
example of the output is reported in figure 4.6.
As discussed in the previous section 4.6, the user is warned about the
unreliability of the model when the SAMP score is between -3.92 and -1.39.
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Stirling ALD Mortality Predictor (SAMP)
Mortality risk model after 28 days from admission in hospital 
for patients suffering from alcoholic liver disease during acute 
hepatitis
Severe form of alcoholic hepatitis in patients with alcoholic liver disease is associated with high 
mortality; it is therefore vital to identify patients at greatest risk of mortality as they may benefit 
from aggressive intervention. This new predictive model, which uses four statistically significant 
predictors, could be used in clinical practice to identify such patients. The comparison with the 
available predictive scores showed an increase of 25% predictive power, demonstrating increased 
accuracy in identifying these sick patients with alcoholic hepatitis.
1. Level of creatinine at admission:  micromoles per litre
2. Level of creatinine on 7th day:  micromoles per litre
3. Prothrombin time:  seconds
4. Is the patient suffering from encephalopathy?
Yes No
 
Developed by Thomas Mazzocco and Amir Hussain, University of Stirling. All rights reserved. 
Pilot prototype provided "as is" without any warranty. 
Calculate score
Figure 4.5: Input screen for ALD mortality predictor
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Stirling ALD Mortality Predictor (SAMP)
Mortality risk model after 28 days from admission in hospital 
for patients suffering from alcoholic liver disease during acute 
hepatitis
SAMP score: -1.149
The probability of death within 28 days from admission is about 24% 
A score of -4.6 or 4.6 corresponds respectively to a probability of death of about 1% or 99%.
A score of -2.9 or 2.9 corresponds respectively to a probability of death of about 5% or 95%.
A score of -2.2 or 2.2 corresponds respectively to a probability of death of about 10% or 90%.
Back 
Developed by Thomas Mazzocco and Amir Hussain, University of Stirling. All rights reserved. 
Pilot prototype provided "as is" without any warranty. 
Figure 4.6: Output example for ALD mortality predictor
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4.8 discussion
In the developed CDSS, we first determined the optimal number of variables,
selecting four relevant variables: after applying a cross-validation strategy, as
recommended in section 3.3, we had evidence that there is no benefit (in terms
of model performance) in including more than 4 variables in the model, so
we chose the smallest number of variables which can guarantee the highest
predictive power. It has to be noted at this stage that, while the selected
variables are definitely significant in predicting the outcome, nothing could
be certainly stated about the excluded variables: the size of the considered
dataset prevented us from including more variables in the model, as this could
have led to an unreliable model. Further studies with datasets including more
patients are now required to investigate if other variables may further improve
the developed model as well as to validate the proposed model.
Previous studies [68, 66] have shown the usefulness of repeating scoring
systems after one week of admission to predict outcome. Some variables
recorded after admission have been included in the model: two variables
(namely, creatinine level and prothrombin time) out of the four selected for
the model were recorded after admission, confirming that a second evaluation
of these parameters provided significant predictors for calculating 28 day
mortality risk. Most of the patients with severe AH died within 7 days of
admission (20 out of 37), as severe AH is associated with early mortality.
The significance of re-evaluating these parameters is to continuously assess
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effectiveness of treatment commenced on admission: the proposed score can
be calculated up to 7 days after admission. If the score is improving then it is
worth continuing treatment, otherwise depending on the general condition and
other co-morbidities of the patients, a decision is taken either to withdraw the
treatment or escalate to other major interventions such as liver transplantation.
In most studies (such as [56, 59]) 28-day survival is used to predict long term
outcome in these patients: the comparison of the proposed score calculated for
patient alive after 28 days and dead within 28 days highlighted a statistically
significant relationship between the output of the proposed model and the
actual mortality (p < 0.001).
While creatinine level and prothrombin time were already known to be
predictors of 28 day mortality in patients with AH, and indeed they were also
included in currently used predictive models, encephalopathy was not used
as its assessment is very subjective especially at an earlier stage. However,
since the presence of this condition has been selected as one of the four most
significant predictors among all collected variables, it is believed that such
variables should be included in the proposed model.
The comparison with the available predictive scores evaluated at admission
showed an increase of 25% in predictive power (evaluated as suggested in
section 3.4), suggesting that the inclusion in the model of variables evaluated
after admission and the subsequent use of an appropriate variables selection
procedure, as detailed in paragraph 3.1.3, may significantly improve the
performance of such models.
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Finally, according to the procedure described in section 3.5, an a posteriori
analysis about misclassifications distribution was carried out: this identified a
region in the output domain where the developed model is unreliable and its
usage is discouraged.
4.9 conclusion
Significant number of patients with AH succumb to early death because of
hepatic inflammation and its complications, therefore early identification of
these patients with the view of intensive intervention and management can
lead to enhanced survival through the use of steroids or intensive treatment
of complication of AH [69].
The proposed model combines for the first time variables collected at
admission and up to 7 days after admission in order to build a more accurate
prediction of mortality for patients during AH episodes. Also, the presence of
encephalopathy has been included for the first time in the number of predictors.
The final model, which includes four variables selected according to the best
practices identified in paragraph 3.1.3, has shown a noticeable improvement in
considered performance metrics outperforming the gold standard benchmark
models.
In conclusion, the capability of employing logistic regression based mortality
prediction model for patients with AH has been ascertained and a potential
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impact is envisaged from this work both for clinical practice and further
research.
A future large-scale study is required to clinically validate the results from
this study and to assess the feasibility of deploying such a model in real clinical
practice, additionally yielding new and potentially useful clinical insights (e.g.
through the analysis of considered and excluded variables).
5
C A S E S T U D Y 2 : A P R E D I C T I V E M O D E L T O A I D T H E
D I A G N O S I S O F D E M E N T I A
This chapter describes the second case study used to validate the proposed
framework. The developed predictive model is designed to aid the diagnosis of
early dementia, as clinicians often experience difficulties in such diagnosis due
to the intrinsic complexity of the process and lack of comprehensive diagnostic
tools.
Different models have been proposed to provide medical decision support in
dementia diagnosis. The aim of this study is to improve on the performance of
a recent application of Bayesian belief networks using an alternative approach
based on logistic regression.
A pool of 14 variables has been evaluated in a sample of 164 patients suspec-
ted of dementia. First, a logistic regression model for dementia prediction is
developed using all variables included in the previous model; then, a second
model is built using a stepwise logistic regression starting with all collected
variables and selecting the pool of the relevant ones. A range of performance
metrics have been used to evaluate the developed models.
The new models have resulted in very good predictive power, demonstrating
general performance improvement compared to a state-of-the-art prediction
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model. Interestingly, the approach based on statistical variables selection
outperformed the model which used variables selected by domain experts in
the previous study.
5.1 background
Diagnoses of the common dementias of old age are operationally defined
on the basis of different symptoms and neuropsychological profiles; in this
process, clinicians use various sources of evidence in the reasoning process,
which include evidence-based clinical guidelines, often supplemented by
individual consultations [70].
General practitioners play a pivotal role in establishing diagnosis of de-
mentia and in providing ongoing support and intervention. Nonetheless,
substantial literature [71, 72] shows their difficulties in fulfilling this role,
especially for early detection of dementia.
Since one of the reasons for this is the lack of readily available diagnostic
instruments [73], efforts have been made to explore different screening meas-
urements and methods.
Different models have been proposed to provide decision support for the
diagnosis of dementia. An application of Support Vector Machines (SVMs) has
been studied in a study [74] which compared a fully automated computer-
based diagnosis system for dementia pathologies using neuroimages with
the diagnostic classification made by six radiologists with different levels of
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experience. Three different datasets were considered for comparative analysis
between SVMs and radiologists; in the first two sets, the task was to detect
sporadic Alzheimer’s disease: SVMs correctly classified 95% of the cases versus
the 65% to 95% of radiologists in the first set while in the second set SVMs
showed an accuracy of 93% compared to the 80% to 90% scored by radiologists.
Finally, the SVM was asked to separate patients with sporadic Alzheimer’s
disease from those with frontotemporal lobar degeneration: SVMs scored an
accuracy of 89% versus the 63% to 83% of radiologists. These results are not
directly comparable with the model object of the present study (whose aim is
the diagnosis of generic dementia conditions), but they do demonstrate the
potential of machine learning techniques applied to this medical domain (often
outperforming specialists’ predictions), showing also that no prior knowledge
is required to be included in the model in order to construct a good prediction
tool.
Another study [75] built a computer-based model which could provide a de-
mentia diagnosis according to DSM-IV criteria formulated in 1994 by American
Psychiatric Association and to the 10/66 dementia survey [76] in order to make
a comparison between them. While the DSM-IV criteria are regarded as a gold-
standard and used as a benchmark, the 10/66 dementia diagnostic algorithm
takes into account a structured clinical mental state interview, a cognitive
test battery, different informant interviews, a neurological assessment and a
questionnaire to detect behavioural and psychological symptoms: the results
from this screening tests are then used to make a prediction on dementia
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diagnosis by means of a logistic regression equation previously developed in a
pilot study. The tool has shown a sensitivity of 57.8% and a specificity of 98.3%
using the implementation of the DSM-IV criteria; a sensitivity of 93.2% and a
specificity of 96.8% was recorded using the 10/66 criteria. Although the very
different number and type of collected variables prevent us from a comparison
with the results of the present study (where a limited number of variables
is collected), however, this application shows that a model based on logistic
regression (and so without a prior built-in knowledge) could outperform the
gold-standard guidelines.
A novel application (called DemNet) of Bayesian Belief Networks (BBN) to
provide medical decision support for the diagnosis of dementia in primary
care practice has been recently proposed [77]; this was built as a "hand-crafted"
model, since it relies on domain experts’ knowledge.
A BBN is a representation of complex domains that are characterised by
uncertainty which enables inference of future uncertain events based on prior
related known events. More formally a BBN includes a set of nodes (or vertices)
that represent the domain variables, a set of directed edges which represent
dependency relationships between the variables and a set of local probability
tables, one table per variable, which quantitatively encodes the strength of
each dependency relation [78]. Standard benchmarks have shown that good
results are achieved in the diagnosis of dementia using BBN. The developed
model was implemented in a software system designed to be used by clinical
practice nurses involved in the primary level assessment of patients suspected
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of having dementia; in an attempt to optimise user friendliness and utility
in a busy primary care setting, the model sought to use numerically few
parameters which are consistent with a reasonably high diagnostic accuracy
[79].
The setting of this last application is quite agile (given the small amount
of information required to make a prediction) when compared with the
previously cited studies. However, they required both technical expertise
and domain experts’ knowledge for building the more sophisticated and
complex Bayesian belief network model.
5.2 aims
The present study builds on the abovementioned previous research and its aim
is to design, through an appropriate variables selection, a novel model that can
outperform the considered benchmark hand-crafted model. Consequently, a
performance improvement is expected using the same dataset and a common
set of performance metrics.
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5.3 dataset preparation
5.3.1 Study sample
The collection of data has been carried out as part of a previous research
work [80]: 164 patient records from clinical practice were obtained from the
Community Mental Health Team Elderly (CMHTE), Kildean Hospital, Stirling.
A clinical protocol detailing the data requirements was developed and the
necessary governance process was followed. Local Ethical Research Council
approval was granted. Community Psychiatric Nurses (CPNs) from CMHTE
agreed to collect the data, as it aligned with the diagnostic variables that they
recorded during initial assessment of patients where dementia was suspected.
Each completed record consisted of the CPNs initial assessment, as well as
the actual diagnosis provided by a CMHTE diagnosing physician. It is worth
noting that the data regarding 50 out of 164 patients were not fully provided:
at least one value from collected variables was missing; when possible (i.e.
there are no missing data for selected variables), records with missing data
will be used in this study.
5.3.2 Collected variables
A set of 14 parameters has been evaluated within the considered sample
of patients: specifically, 3 variables from standard tests (Mini-Mental State
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Examination, Hachinski Ischemic Score and Clock Drawing Test), 8 qualitative
variables (investigating the ability to carry out personal and domestic activities
of daily living, the current and subtle functioning, the global severity and
the possible presence of psychosis, memory impairment or tremors) and 3
variables about patients’ clinical condition and history (age of each patient,
duration of symptoms and whether they experienced a clear progression in
symptoms) were collected. Collected variables from standard test are:
• cognitive impairment (CI), which represents the result of the Mini-Mental
State Examination (MMSE), used for detection of dementia in individuals
with suspected cognitive impairment [81], measured as the ratio between
the score of the test and the maximum attainable score
• clock drawing test (CDT ), which is used combined with the result
of MMSE in screening for mild dementia [82]; the result of the test
is mapped as a dummy variable which states if the patient could
successfully complete the test or not
• Hachinski Ischemic Score (HI), which is generally used to discriminate
Alzheimer’s disease from vascular dementia [83]; the result of the test
has been normalized between 0 and 1
Qualitative variables which have been collected are:
• domestic activities of daily living (DADL), which reflects the individual’s
ability to carry out activities such as shopping, housekeeping, finance
management, food preparation and transportation
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• personal activities of daily living (PADL), which reflects the individual’s
ability to carry out activities such as dressing, eating, ambulating and
hygiene
• current functioning (CF), which reflects the individual’s ability to func-
tion in daily life aggregating PADL and DADL
• subtle functioning (SF), which captures evidence of subtle changes in
cognition such as progressive difficulty in balancing a cheque book
• global severity (GS), which represents the global severity of impairment;
aggregates CF, CI and SF
These five categorical variables can represent three levels of impairment:
severe, mild, none. Each of them has been mapped with two dummy variables,
according to the procedure described in paragraph 3.1.1, the first one showing
if at least a mild impairment was present (adding the suffix "m" to the variable
name) and the second one stating if a severe impairment was present (adding
the suffix "s").
The other recorded qualitative variables are:
• psychosis (PS), which captures non-cognitive symptoms associated with
dementia such as impaired connection to reality, auditory or visual
hallucinations and delusions; the variable is mapped with two dummy
variables: the first one showing if symptoms are at least equivocal (PSe)
and the second one stating if they are definitely present (PSp)
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• memory impairment (MI), which records the possible presence of memory
impairment (binary variable)
• tremors (TR), which records the possible presence of tremors (binary
variable)
Finally, some data about history and clinical conditions of patient are
recorded:
• age (AG), which records the age of patient expressed in years
• duration (DR), which records the duration of symptoms mapped with
two dummy variables: the first showing at least a medium duration
(DRm) and the second one a long duration (DRl)




A logistic regression has been carried out to determine the vector of coefficients
which in the considered dataset could associate each record (a patient) with
the probability of experiencing dementia. For the purpose of this work, PASW
Statistic (SPSS) has been used for the analyses. As required in paragraph
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3.1.2, preliminary statistical tests were carried out in order to identify possible
collinearity between variables.
5.4.2 Variables selection
Since the previous work - DemNet - initially made an expert-driven variables
selection, logistic regression has been carried out in this study in two stages.
In the first stage, only those variables involved in dementia prediction in
the previous research were employed with the aim of investigating whether
logistic regression could outperform the previous model. In the second stage,
as recommended in paragraph 3.1.3, all available variables are used to carry out
a backward stepwise logistic regression in order to select the most significant
ones: the aim of this second step was to check whether the optimal subset
was selected or if some of them need to be included or removed. This second
model could possibly improve the global model performance and/or select a
restricted pool of variables which could give comparable performance while
requiring collection and elaboration of a smaller number of variables.
5.4.3 Model validation
As required by the proposed framework in section 3.3, the predictive power of
the model has been assessed across different samples (using stratified cross-
validation). The dataset has been split into three parts (evenly distributing
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positive and negative outcomes) and two out of three thirds are cyclically
selected to run the logistic regression and the remaining third is used to test
the results: in this way, the whole dataset is used once to test the model.
5.4.4 Model evaluation
As prescribed by section 3.4, the area under ROC curve is used for this study as
a performance metric. True positive/negative rates as well as positive/negative
predicted values are also reported. Also, accuracy computed using a threshold
of 0.5 is reported in order to allow comparison with previous studies.
5.5 results
In order to verify the presence of any candidate predictor which provides
incomplete information with regard to the outcome, a cross-tabulation of all
categorical variables has been built showing that CFm and GSm present only
0 and 1 cases respectively of patients affected by dementia who have these
two variables equals to zero. For this reason, these two variables could make
the model unreliable and this would be reflected in the abnormal standard
deviation of the computed coefficients. These two variables have been dropped;
however, since in the considered dataset they were combining effects from
other variables, this removal is not expected to significantly decrease the model
performance.
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Collinearity diagnostics have been run by means of the appropriate function
of PASW Statistic (SPSS), returning tolerance and VIF values. Since criteria
mentioned in the previous paragraph 3.1.2 are satisfied for all variables, they
appear not to be collinear.
The used dataset presents an uneven class distribution, since patients with
dementia are 135 out of 164 and only the remaining 29 are not affected by
this pathology. This means that the class distribution is around 1:5 and, in
principle, this does not seem to be a problem for building a reliable classifier
[84]. A check can be carried out in due course to verify that the dataset has a
sufficient number of events per variable: as mentioned in paragraph 3.1.3, a
rule of thumb suggests that the number of the less common of the two possible
outcomes divided by the number of predictor variables should be at least 10;
for a given set of data, introducing more variables will generally produce a
better fit to the data but an excessive number of variables may overfit the
dataset, leading the model to lose its generalisation power.
In the first stage, logistic regression has been carried out using only the
variables employed in the previous model (DemNet) to investigate if this
technique could provide an improvement.
The previous model used PADL, DADL, CF, CI, CDT , SF, GS, AG, DR, CP.
Although variables like CI and AG are continuous and dividing them into
subclasses could cause a consequent loss of information, in order to have the
fairest possible comparison, for the purpose of this first logistic regression
study, these variables have been divided as in the original DemNet model: CI
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is thus mapped to two dummy variables, namely CI1 and CI2, denoting if
the patient could score at least one or two thirds of the maximum attainable
score of the MMSE test. AG is now mapped to 3 dummy variables, namely
AG1, AG2 and AG3, representing if the patient is more than 64, 74 or 84 years
old respectively. According to the new variable mapping scheme, the used
variables are: PADLm, PADLs, DADLm, DADLs, CFs, CI1, CI2, CDT , SFm,
SFs, GSs, AG1, AG2, AG3, DRm, DRl, CP.
Following cross-tabulation, it is seen that AG1 assumes the value 0 only
three times within all records and never within patients without dementia;
for this reason, this variable has been dropped. The result of the regression
analysis is tabulated in the table 5.1.
The considered dataset has 164 observations, but only 29 of them are cases
of patients without dementia; so the ratio between number of events and
considered variables (16) for this particular dataset is 29/16 = 1.813. Since this
value is quite low the risk of overfitting data could be high: for this reason
and in order to validate and test the new model, an appropriate validation
strategy has been set up as previously discussed.
The accuracy (percentage of correct predicted outcomes, based on a threshold
of 0.5) of the model computed on the unseen data is 86.0%, which outperforms
the 75.0% accuracy score of the previous benchmark model. The AUC of the
model is 0.783 again outperforming the previous model (0.764).
For completeness, it is also reported that the accuracy computed on the
data used for computing the coefficients is 90.7% with an AUC of 0.907,
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variable coefficient std. error Wald p value
DADLm -.495 1.658 .089 .765
DADLs -1.865 1.069 3.041 .081
PADLm 1.957 .857 5.220 .022
PADLs -.482 1.269 .145 .704
CFs 2.523 1.201 4.410 .036
CI1 .092 1.378 .004 .947
CI2 -.838 .873 .922 .337
CDT -1.702 .876 3.773 .052
SFm -1.564 2.201 .505 .477
SFs -1.221 1.188 1.055 .304
GSs -1.015 1.130 .806 .369
AG2 1.598 1.052 2.307 .129
AG3 -1.886 .862 4.784 .029
DRm 3.129 1.687 3.439 .064
DRl .231 .704 .107 .743
CP 3.376 .788 18.347 <.001
Constant -1.954 2.453 .634 .426
Table 5.1: Results from logistic regression using expert driven variables selection
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with evidence of a degree of overfitting. According to Cox and Snell [85] the
averaged R2 for the model computed on the whole dataset is 0.371, while using
the R2 measure proposed by Nagelkerke [86] the model scores 0.602.
In the second stage, stepwise logistic regression starting with all available
variables has been carried out to perform a variables selection; the idea
is to select only the variables which can improve significantly the model
performance, leading to a more efficient and cost-effective model. Removal
probability of the stepwise algorithm is fixed at 0.2 and variablesAG and CI are
included in the model as continuous variables to ensure no loss of information.
The algorithm met the selection criteria after 12 iterations and selected 8
variables which are tabulated in the table 5.2 along with the coefficients and
Wald statistics of the logistic regression executed only with those variables.
Comparing the pool of selected variables with the previously used one, we
note that:
• CI, SF, AG, were included in the previous model but do not improve the
logistic regression model’s performance
• TR, not included in the previous model, significantly improved the model
performance
• DADL, included in the previous model, is relevant only if reflects a
severe impairment
• PADL, included in the previous model, is relevant only if reflects an
impairment judged at least mild
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variable coefficient std. error Wald p value
DADLs -2.009 1.120 3.218 .073
PADLm 1.390 .745 3.477 .062
CFs 2.233 1.171 3.633 .057
GSs -1.589 .941 2.851 .091
TR -2.517 .942 7.141 .008
DRm 1.806 1.038 3.028 .082
CP 3.875 .800 23.474 <.001
CDT -1.704 .833 4.182 .041
Constant -2.348 1.113 4.449 .035
Table 5.2: Results from logistic regression using statistics driven variables selection
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variable coefficient p value
average std. error average std. error
DADLs -2.315 1.724 .261 .273
PADLm 1.357 .312 .185 .175
CFs 2.494 2.362 .324 .426
GSs -1.905 1.323 .278 .329
TR -2.661 .846 .074 .098
DRm 2.529 1.902 .190 .047
CP 4.334 1.514 <.001 <.001
CDT -2.091 .709 .089 .036
Constant -3.009 1.873 .117 .014
Table 5.3: Summary of regressions with three subsets
• DR, included in the previous model, is relevant only if it reports at least
a medium duration
The ratio between number of events and considered variables is higher than
before (29/8=3.625) since less variables are involved, but it is still quite low.
Again, to evaluate the model performance only with the selected variables, the
above mentioned cross-validation approach has been implemented in order to
avoid overfitting. Results from the different regression models using each of
three datasets are averaged and summarized in the table 5.3.
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Figure 5.1: TPR and TNR values for different thresholds
The accuracy of the model computed on unseen data is 90.2% and the
AUC of the model is 0.879, outperforming the logistic regression model with
expert-driven variables selection. It is also found that the accuracy computed
on the data used for computing the coefficients is 91.5% with an AUC of
0.905, outlining a possible certain degree of overfitting which has been avoided
with cross-validation. The R2 for the model is 0.365 according to Cox and
Snell, while the model scored 0.601 according to Nagelkerke. Figures 5.1 and
5.2 report true positive/negative rates (TPR and TNR) and positive/negative
predictive values (PPV and NPV) while the threshold is varied. The model is
reported to outperform the benchmark model for threshold between 0.91 and
0.94.
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Figure 5.2: PPV and NPV values for different thresholds
Since in both models the selected variables are all categorical, the model to








coefficients of positive answers (5.2)
The final model consists then of a number (one per variable) of yes/no
questions regarding the patient suspected of dementia. It is necessary to sum
up all the coefficients associated with the questions where the answer is
positive and add a constant in order to get the final score; this should be finally
inserted in the formula 5.2 to get the probability of patient being affected with
dementia.
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5.6 misclassification analysis
We investigate how predictions and misclassifications are distributed in
order to determine whether the model could be unreliable under certain
conditions. We choose to study such distributions as a function of the model
output. Operatively, the entire range of outputs has been divided into 10
categories uniformely distributed between the minimum and maximum values
of obtained output values: considering SCORE (as defined per formula 5.2) as
model output, the interval to be divided into 10 categories is [0, 1]; considering
P(Y) (as defined per formula 5.1) we focus on the interval identified by the
extreme model output given using the considered dataset. For this analysis
we have chosen representative thresholds τ of 0.5, 0.7 and 0.9.
The distribution of misclassifications is reported in the following tables 5.4
and 5.5.
interval min 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
interval max 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
% misclassif. τ = 0.5 0.0 - 62.5 45.5 - - 20.0 33.3 12.5 3.5
% misclassif. τ = 0.7 0.0 - 62.5 45.5 - - 80.0 33.3 12.5 3.5
% misclassif. τ = 0.9 0.0 - 62.5 45.5 - - 80.0 66.7 87.5 3.5
Table 5.4: Distribution of misclassifications (function of P(Y))
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interval min -4.1 -3.0 -1.9 -0.8 -0.4 1.5 2.6 3.7 4.8 5.9
interval max -3.0 -1.9 -0.8 -0.4 1.5 2.6 3.7 4.8 5.9 7.0
% miscl. τ = 0.5 0.0 0.0 62.5 45.5 27.3 14.3 2.5 5.0 0.0 0.0
% miscl. τ = 0.7 0.0 0.0 62.5 45.5 54.5 14.3 2.5 5.0 0.0 0.0
% miscl. τ = 0.9 0.0 0.0 62.5 45.5 72.7 57.1 2.5 5.0 0.0 0.0
Table 5.5: Distribution of misclassifications (function of SCORE)
The distribution of misclassifications and predictions for the defined inter-
vals are reported (respectively for t equal to 0.5, 0.7, 0.9) on figures 5.3, 5.5 and
5.7 for intervals of P(Y), and on figures 5.4, 5.6 and 5.8 for intervals of SCORE.
From the analysis of the distributions function of P(Y), it is clear that the
first and last intervals has a lower proportion of misclassification than other
intervals. More specifically, the interval of SCORE between -1.85 and 2.55 (or
1.45 depending on the chosen threshold) has a very high misclassification
rate, suggesting that the developed model is not reliable at such an interval
of output. Excluding the interval between -1.85 and 2.55 (where 27% of
predictions are concentrated), and assuming a threshold of 0.5, the accuracy
increases from 89.0% to 97.5%.
This information should be used to refine the model: in the implementation
proposed in the next section 5.7, it is used to suggest the use of alternative
tools to detect early dementia conditions. Further studies should collect more
data, in order to reach a sufficient dataset size to build a possible second









































































Figure 5.4: Distribution predictions/misclassifications τ = 0.5 (function of SCORE)









































































Figure 5.6: Distribution predictions/misclassifications τ = 0.7 (function of SCORE)









































































Figure 5.8: Distribution predictions/misclassifications τ = 0.9 (function of SCORE)
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model to be used downline of the proposed one, with a view to improve the
accuracy of the model.
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5.7 implementation
The model developed within this chapter to aid the diagnosis of dementia has
been implemented into a calculator named Stirling dementia risk calculator. It is
a web-based prototype and its core is a PHP script, which generates an HTML
page after data is collected from a HTML input form and then POSTed when
user presses the "Calculate score" button.
The prototype, available at http://bit.ly/dem-calc, is intended to be used
for patients suspected of having dementia. The user is asked to answer
8 categorical questions, specifically: level of impairment in domestic and
personal activities of daily living, level of impairment in current functioning,
level of global severity of impairment, the presence of tremors, the presence of
a clear progression of symptoms, the ability of completing the clock drawing
tests, the duration of symptoms (short, medium or long period). Levels to
describe impairment are: severe, mild and none.
These variables are then mapped to identify the coefficients to be summed
together as per formula 5.2. Specifically, with regard to figure 5.9 (which
shows the user interface) and table 5.3 (which reports variables included in
the model):
• DADLs coefficient is summed if answer to question 1 is "severe"
• PADLm coefficient is summed if answer to question 2 is "severe" or
"mild"
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• CFs coefficient is summed if answer to question 3 is "severe"
• GSs coefficient is summed if answer to question 4 is "severe"
• TR coefficient is summed if answer to question 5 is "yes"
• DRm coefficient is summed if answer to question 6 is "medium" or "long"
• CP coefficient is summed if answer to question 7 is "yes"
• CDT coefficient is summed if answer to question 8 is "yes"
The tool calculate the probability of having dementia using formula 5.1,
reporting it to user in a separate screen as in figure 5.10. As suggested from
the analysis carried out in the previous section 5.6, the user is warned about
model unreliability when the value of SCORE is between -1.85 and 2.55.
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Stirling Dementia Risk Calculator
Risk model for patients suspected of having dementia
1. Is the patient showing impairment in domestic activities of daily living (ability to carry out activities such as 
shopping, housekeeping, finance management, food preparation and transportation)?
Severely Mildly None
2. Is the patient showing impairment in personal activities of daily living (ability to carry out activities such as 
dressing, eating, ambulating and hygiene)?
Severely Mildly None
3. Overall, is the patient showing impairment in current functioning, i.e. in general activities of daily living?
Severely Mildly None
4. Overall, how would you rate the global severity of impairment?
Severe Mild None
5. Is the patient experiencing tremors?
Yes No
6. How long has the patient been showing symptoms for?
Short period Medium period Long period
7. Did the patient show a clear progression in these symptoms?
Yes No
8. Is the patient able to complete the clock drawing test?
Yes No
 
Developed by Thomas Mazzocco and Amir Hussain, University of Stirling. All rights reserved. 
Pilot prototype provided "as is" without any warranty. 
Calculate score
Figure 5.9: Input screen for dementia risk calculator
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Stirling Dementia Risk Calculator
Risk model for patients suspected of having dementia
The probability of suffering from dementia is 3%
The most important factors with respect to the outcome are:
• the presence of tremors (negative correlation)
• the medium/long duration of symptoms (positive correlation)
• the impairment in personal activities of daily living (positive correlation)
Back 
Developed by Thomas Mazzocco and Amir Hussain, University of Stirling. All rights reserved. 
Pilot prototype provided "as is" without any warranty. 
Figure 5.10: Output example for dementia risk calculator
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5.8 discussion
The first fact which appears from the analysis of the results is that logistic
regression clearly outperforms the performance of a Bayesian belief network,
which was regarded as a state-of-the-art model. Unlike other artificial intelli-
gent techniques commonly used for prediction known as “black-box” models
(such as neural networks or support vector machines), logistic regression
provides with a clear picture of which variable is significant (with the corres-
pondent p-value) for the final predicted outcome, giving also a measure of the
magnitude and the direction (reflected by the coefficient with its sign) of such
impact.
The added value of the developed model which led to a performance
increase is determined both by the selected technique and by the variables
selection process, which followed all the indications suggested by the proposed
framework in section 3.1.
The differences between variables selected by domain experts and by a
statistical-driven approach have already been outlined. The most relevant
difference is the inclusion of TR in the group of significant variables, with
an inverse relationship to the probability of a positive diagnosis of dementia.
The statistical-driven approach has shown the best performance in terms of
predictive power and accuracy and a good R2 coefficient. An approach with
fewer variables (like the proposed statistical-driven one) could be cheaper to
implement and employ: in this case, the workflow from the collection of data
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to the provision of a predicted outcome will use fewer resources (in terms of
time and money) than an approach which requires more data.
Comparing p-values provided on table 5.2 with the ones tabulated on table
5.3, it is clear how significance of each variable could be highly influenced
by the size of the considered sample: considering the whole dataset, all the
selected variables could be regarded as significant (when choosing a criterion
of p < 0.1) while considering datasets composed by two thirds of the original
dataset, only few variables could be said to be definitely significant. Again,
looking at table 5.1, only a handful of variables could be regarded as definitely
significant while nothing could be certainly stated about the significance
of most coefficients; possibly, a bigger dataset could give further help in
discrimination between significant and non significant variables. Also, since
the criterion suggested in paragraph 3.1.3 about ratio between number of data
points and number of independent variables is not met, a larger dataset should
be used to strengthen findings.
The size of dataset is probably one of the main limitations of this work, which
should then be regarded as a pilot study for further deeper researches. The
final model (both with experts and with statistical driven variables selection) is
relatively simple and could be easily implemented as a decision support system
for carers as shown in the previous section 5.7. Probably the most important
design decision to be determined will be the threshold used to transform the
probability of a positive diagnosis in the actual predicted diagnosis: this choice
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is highly dependent on the assumed costs for type I and II errors (i.e. false
positives and false negatives).
5.9 conclusion
The main aim of this study was to build an alternative model which could im-
prove the results produced by a state-of-the-art Bayesian belief network model
recently developed for dementia diagnosis. The proposed prediction models
used a logistic regression algorithm to predict the diagnosis of dementia using
variables selected either by domain experts or by a statistical driven procedure
following the best practices identified in paragraph 3.1.3. Results have shown a
noticeable improvement in considered performance metrics with the proposed
models outperforming the benchmark hand-crafted model which required
both technical expertise and domain experts’ knowledge for building the
more sophisticated and complex Bayesian belief network model. Interestingly,
the approach based on statistical variables selection outperformed the model
which used variables selected by domain experts in the previous study.
Some limitations should also be acknowledged: first, the considered sample
of patients was quite small (164 patients) leading to a possible dependence
on a specific dataset, with loss of generalization power; a second limitation
relates to the fact that the available data were collected as part of a previous
research, so the motivations behind collecting these specific variables and not
others as well as the exact mapping procedure for qualitative variables are not
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known in details. These two limitations are sufficient to prevent this model
from being directly used in clinical practice; however, the new model offers
fertile ground for further research and development.
In conclusion, whilst the preliminary results reported in this study should
be taken with care, they do demonstrate the capability of employing relatively
simple logistic regression based prediction models for dementia diagnosis and
a range of contributions and potential impact is envisaged from this work
both for clinical practice and further research.
A future large-scale investigation is required to determine the optimal
approach for variables selection and to overcome the discussed existing
limitations imposed by the size of the considered sample; this should also
assess the feasibility of deploying such models in clinical practice.
6
C A S E S T U D Y 3 : A S I D E - E F F E C T S M A P P I N G M O D E L I N
PAT I E N T S R E C E I V I N G C H E M O T H E R A P Y
This chapter presents the third case study developed following the procedure
described in the proposed framework: it is a predictive model used to predict
the probability of experiencing a certain symptom among common side-
effectes in patients receiving chemotherapy.
Cancer treatments are now more effective than ever and, as a consequence,
cancer is becoming a chronic disease. Chemotherapy is a frequently used
treatment in people with cancer and it can cause a number of side-effects
which if not properly managed could have a negative impact on the patients’
quality of life.
A sample of 56 patients receiving chemotherapy treatment for breast,
colorectal and lung cancer is considered; each experienced side-effect is
recorded during four consecutive treatment cycles (each lasting 14 days).
Previous studies have used the same dataset to build side-effects predictive
models for each symptom.
In this study, five of the most frequent side-effects (fatigue, nausea, mucositis,
hand and foot sore, diarrhoea) are selected to build a comprehensive model
which predicts the probability of experiencing a certain symptom on a specified
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day of each cycle of therapy. An overall increase of predictive power is expected
by using an appropriate pre-modelling strategy, i.e. by selecting a proper
functional form of the model.
The computed accuracy of results shows that the newly proposed model
has an enhanced predictive power compared to a state-of-the-art approach.
The information gained from this study will help medical and nursing staff
caring for such patients to more accurately predict the side-effects that patients
will experience and therefore select appropriate help to minimise, whenever
possible, the influence of those symptoms.
6.1 background
It is estimated that in 2007 almost 300,000 individuals in the United Kingdom
were diagnosed with cancer and over the last 25 years, cancer incidents have
considerably increased [87, 88, 89, 90].
Different treatments are available depending on the type and stage of cancer
and the survival rates have been improving over the last 30 years; in particular,
besides surgery an adjuvant chemotherapy treatment is often given: this helps
to reduce the risk of cancer recurrence or death from microscopic spread of
the cancer that is suspected (but cannot be detected) and also it may alleviate
cancer related symptoms with a consequent improvement in patients’ quality
of life [91, 92].
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However, it is to be noted that adjuvant chemotherapy exposes patients to
risk of significant side-effects that could have a negative impact on patients’
quality of life and daily living [93] and also on the maintenance of dose
intensity treatment, which could influence the disease free and overall survival
[94, 95].
A poor assessment and management of symptoms in patients with cancer
have been ascertained [96]. It has also been observed that poorly informed
patients are less likely to comply with treatment and are more likely to
experience anxiety and hence a general reduction in their quality of life
[97, 98]. As a consequence, an effective prediction of side-effects could help
medical staff with better management of patients’ needs, with special regard
to discomfort minimization, unnecessary worry and anxiety reduction.
Different tools have been proposed as clinical decision support system in
many clinical fields: with regard to cancer care, studies tend to focus on
predictors of survival and life threatening toxicities [99, 100, 101].
In relation to the prediction of symptoms, only a few risk models have been
presented [102]. The use of technology to communicate between healthcare
professionals and patients may lead to improvements in quality of life and
symptoms control, reductions in the rate of hospitalizations, emergency depart-
ment visits and cost savings [103]. Patients also appear to have positive views
of using this type of technology, reporting improvements in communication
with healthcare providers [104].
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The Advanced Symptom Management System (ASyMS©) has been de-
veloped and trialled as an example of the use of technology in cancer care
[105, 106, 107, 108]. It has been built as a mobile telephone-based remote
symptom monitoring system which can be used to register, monitor and
predict the side-effects of chemotherapy while the patient is not with a
healthcare professional [109].
First, patients using the system are asked to complete a symptom ques-
tionnaire on a mobile phone twice a day and sent this information directly
to their hospital-based healthcare professional. Self-care advice is then given
on the basis of the reported symptoms. Depending on their seriousness, an
alert is generated to the healthcare professional via a 24 hour dedicated pager
system. The healthcare professional is then informed of the symptoms that the
patient has reported and may contact the patient if necessary. This system also
allows nurses to monitor the symptoms remotely and facilitates the delivery
of relevant and useful advice to the patient based on their current symptoms.
Next, the tool uses the patients’ symptom history as well as a model
developed based on a corpus of patients with similar medical conditions
to predict the likely side effects a patient could expect over the course of
treatment: patients are able to receive predictions concerning the possible
symptoms they are going to experience throughout the course of treatment
along with daily predictions that are updated as they enter data describing
their own symptoms.
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A diary is presented on patients’ mobile phones where, for each day, a
smiley, sad or neutral face is used to depict the overall side-effects situation
predicted for that particular day: patients who wish to plan ahead can see at a
glance which days they are more likely to feel well. Users may select any of
the symptoms to see self-care advice on how to manage this symptom; they
will also be able to see how many more days they are likely to experience each
symptom.
6.2 aims
The aim of this study is to evaluate, improve and generalize the pilot model
proposed by a previous study [110] using an enhanced (including different
cancer conditions) dataset and according to a common set of performance
metrics. In the previous study a number of different simple mathematical
equations were developed to predict the probability of experiencing each
symptom on a specified day of treatment, for patients with breast cancer. The
idea was to build on the previously presented remote monitoring system for
patients.
The objective of the present research is to generalise the previous model to
build a more powerful and comprehensive side-effect risk model for patients
with cancer undergoing adjuvant chemotherapy: this model is not limited
to breast cancer but has been extended to cover colorectal and lung cancer
conditions. A single mathematical model with an appropriate functional form
6.3 dataset preparation 120
developed as recommended in section 3.2, which predicts on a day-by-day
basis the symptoms that patients with cancer receiving chemotherapy are
going to experience, is proposed.
The new model can be used as a tool to provide preparatory information
to patients with cancer receiving chemotherapy and to their carers. An
improvement in the patients’ experience is expected by providing information
on the side-effects that they are likely to experience on each day of treatment;
furthermore, the provision of tailored information and possibly medications
based on their individual needs can also be facilitated in the future by such a
model.
6.3 dataset preparation
The collection of data has been carried out as part of previous research [111],
over a 12-month period from June 2007 to May 2008: 56 patients’ data from
four clinical sites in Scotland were collected, although only 34 patients with
breast cancer were considered within the cited study. Selected patients were
diagnosed with breast, colorectal and lung cancer, starting a course of adjuvant
chemotherapy, aged 18 years or over, able to read and write English and all
deemed by members of the clinical team to be physically and psychologically
fit to participate in the study. Ethical approval was gained from the study sites,
and all patients provided written informed consent before their participation in
the study. The observation of each patient involved treatment over four cycles,
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each lasting 14 days, where treatment was administered at the beginning of
each cycle.
For each patient the following independent variables are used for this study:
• number of the cycle (between 1 and 4), treated as ordinal variable
• number of the day within the cycle (1 to 14), treated as continuous
variable
The dependent variable is the probablity of experiencing symptoms among the
five object of our model. Patients are grouped as follows: patients with breast
cancer (N=34), with colorectal cancer (N=9) and with lung cancer (N=13).
6.4 model construction
6.4.1 Pre-modelling
A previous study [110] has shown that the probability of experiencing a
specific symptom is basically time dependant. In different ways, each of the
five considered symptoms has two main tendencies over time that could be
outlined: a ‘peak effect’, around the day in which the treatment is received
by patients, and an ‘inverted U-shape effect’, rising from a low on the day
after treatment to a peak around mid-cycle before falling again. In this study a
more general model is proposed which combines these two effects. Moreover,
since differences between cycles were outlined, a cycle-dependant coefficient
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was added in order to capture those differences. Following this setting, a
comprehensive model is proposed as per formula (6.1)





- P(d) is the probability of experiencing a specified symptom on day d;
- Dn is a dummy variable which is set to 1 for the n-th cycle and 0 on other
cycles;
- S(d) is a function capturing the ‘inverted U-shape effect’;
- H(d) is a function capturing the ‘peak effect’;
- a, b, cn are coefficients determined for each symptom.
S(d) is built so that S(first day) = S(last day) = 0 and S(middle day) = 1;
in a similar way, H(d) is build so that H(first day) = 1 and H(last day) = 0.
Lots of functions could be adopted to be used as S(d) and H(d). For the
purpose of this study a sinusoid function and a negative hyperbolic function
have been chosen by trial and error.
It is worth noticing that cn is treated as a categorical (ordinal) variable.
As required by the procedure described in paragraph 3.1.1, it should have
been split into 3 binary variables in order to avoid the “dummy variable
trap”. However, since the model does not include an additional constant
and includes only one categorical (ordinal) variable, it is possible to use
the equivalent codification with 4 binary variables without incurring in any
numerical problem. This choice facilitates the analysis of the meaning of model
coefficients.
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Figure 6.1: Chosen functions
Having 14 days within each cycle (and so dmax = 14), the adopted formulas



































The chosen functions are reported in figure 6.1.
6.4.2 Regression
Raw data collected from different patients about symptoms experienced in
the same day of the same cycle have been grouped after dividing the dataset
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into three subsets for breast, colorectal and lung cancer respectively. If they
experienced a certain symptom on that day the considered output was 1,
otherwise 0. After grouping the outputs, these were averaged for each group,
giving a probability of experiencing that symptom at the corresponding time.
It has to be noted that since the target output is a probability (i.e. a real number
between 0 and 1), logistic regression cannot be used for tackling this problem.
Then, a linear regression (one each for breast, colorectal and lung cancer)
based on functional form determined in the previous paragraph 6.4.1 was
run in order to estimate the coefficients for the variables outlined above. As
recommended in paragraph 3.2.1, p-values for each coefficient have been
computed.
Coefficients for regression models are reported on tables 6.1, 6.2 and 6.3.
6.4.3 Model evaluation and validation
The outcome of the model is the probability of experiencing a specified
symptom on a specified day and cycle.
For each symptom, the receiver operating characteristic (ROC) curve has
been used to estimate the predictive power of the newly developed model, as
prescribed by the proposed framework in section 3.4. Given the size of the
dataset (especially for colorectal and lung cancer conditions), a leave-one-out
cross-validation has been selected for model validation.
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Table 6.1: Regression coefficients for breast cancer regression model
Diarrhoea H&F sore Mucositis Nausea Fatigue
S 0.023 0.048 0.186 0.192 0.135
H -0.025 -0.042 -0.263 0.474 0.085
D1 0.051 0.043 0.262 0.027 0.198
D2 0.065 0.071 0.124 0.051 0.287
D3 0.035 0.080 0.203 0.010 0.369
D4 0.073 0.070 0.311 0.075 0.286
The area under ROC curve has also been used to compare the performance
of the developed models with the previously used ones. It has to be pointed
out that since patients in the same group (i.e. during the same day of the same
cycle) may have experienced different symptoms, the ideal AUC=1.0 cannot
be reached.
Moreover, in order to measure the goodness of fit and to better explain the
predictive power of the model, the standard coefficients of determination (R2)
are also computed for each model.
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Table 6.2: Regression coefficients for colorectal cancer regression model
Diarrhoea H&F sore Mucositis Nausea Fatigue
S 0.070 -0.072 0.010 -0.065 0.136
H -0.098 0.022 0.025 -0.081 0.014
D1 0.117 0.083 0.031 0.089 0.102
D2 0.076 0.145 0.073 0.150 0.052
D3 0.122 0.215 0.116 0.206 0.040
D4 -0.004 0.081 -0.010 0.052 0.009
Table 6.3: Regression coefficients for lung cancer regression model
Diarrhoea H&F sore Mucositis Nausea Fatigue
S 0.032 0.022 0.077 0.015 -0.006
H 0.014 0.031 -0.015 0.024 -0.155
D1 0.007 0.152 0.216 0.203 0.468
D2 0.056 0.139 0.316 0.193 0.588
D3 0.003 0.122 0.281 0.159 0.581












Figure 6.2: Comparison of performance for each symptom
6.5 results
6.5.1 Area under ROC curve
On table 6.4 the AUC for the proposed model and for the previously used
model is reported for each symptom. In order to make a fair comparison with
the available benchmark (which used only patients with breast cancer), the
performance related to breast cancer are also evaluated separately. From the
results tabulated on table 6.4 and also depicted in figure 6.2, it is clear that the
proposed model significantly outperformed the previous model.
6.5 results 128
Table 6.4: AUC for current and previous models
# Diarrhoea H&F sore Mucositis Nausea Fatigue
1 0.658 0.638 0.714 0.710 0.690
2 0.596 0.598 0.696 0.710 0.596
3 0.524 0.529 0.565 0.687 0.560
#1: proposed model - breast, colorectal and lung cancer
#2: proposed model - breast cancer only
#3: previous model - breast cancer only [110]
6.5.2 R2 and p-values
Coefficients of determination for each symptom and type of cancer are given
in table 6.5 (in this case, the R2 coefficients measures the proportion of the
variability in the dependent variable about the origin explained by regression -
since the coefficients for identifying the cycle are treated as dummy variables -
and so this coefficient cannot be compared to a similar one for models which
include an intercept).
Each coefficient derived from the linear regression is associated with a p-
value, showing the probability of observing the data if the associated coefficient
6.5 results 129
Table 6.5: Comparison of R2
Diarrhoea H&F sore Mucositis Nausea Fatigue
Breast 0.746 0.837 0.900 0.850 0.960
Colorectal 0.595 0.686 0.742 0.721 0.588
Lung 0.469 0.836 0.910 0.796 0.960
Table 6.6: P-values for breast cancer regression model
Diarrhoea H&F sore Mucositis Nausea Fatigue
S 0.227 0.016 0.001 0.001 0.001
H 0.314 0.101 <0.001 <0.001 0.088
D1 0.006 0.022 <0.001 0.588 <0.001
D2 0.001 <0.001 0.012 0.305 <0.001
D3 0.057 <0.001 <0.001 0.836 <0.001
D4 <0.001 <0.001 <0.001 0.132 <0.001
was equal to zero. So, a high p-value indicates that the variable associated to
the coefficient does not improve the global model.
P-values associated with each coefficient are tabulated on tables 6.6, 6.7 and
6.8.
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Table 6.7: P-values for colorectal cancer regression model
Diarrhoea H&F sore Mucositis Nausea Fatigue
S 0.149 0.051 0.655 0.024 0.938
H 0.125 0.639 0.392 0.035 0.671
D1 0.012 0.018 0.147 0.001 <0.001
D2 0.099 <0.001 0.001 <0.001 0.030
D3 0.009 <0.001 <0.001 <0.001 0.090
D4 0.934 0.020 0.626 0.054 0.702
6.5.3 Analysis
Data about cycle and day of treatment seem to have a good (and sometimes
excellent, considering that the maximum attainable AUC is less than 1)
predictive power for all the listed symptoms.
Also, the overall performance of the model seems to confirm that the effects
observed for treatments of breast cancer (inverted U-shape and peak effects)
may be re-usable for other kinds of cancer. However, as reflected by the lower
R2 (especially for colorectal cancer) these effects may be able to explain a
smaller part of the variability of the proposed model.
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Table 6.8: P-values for lung cancer regression model
Diarrhoea H&F sore Mucositis Nausea Fatigue
S 0.209 0.454 0.075 0.760 0.915
H 0.672 0.423 0.795 0.704 0.038
D1 0.784 <0.001 <0.001 <0.001 <0.001
D2 0.024 <0.001 <0.001 <0.001 <0.001
D3 0.891 <0.001 <0.001 0.001 <0.001
D4 0.269 0.293 0.016 <0.001 <0.001
Moreover, p-values associated with coefficients show that the two main
effects, while being statistically significant for many symptoms in patients
with breast cancer, could not be generally seen as definitely relevant during
the treatment of colorectal or lung cancer (assuming a significance level of
5%), except for both effects in determining nausea for patients with colorectal
cancer and for inverted U-shape effect in prediction of fatigue for patients
with lung cancer.
Two examples of the model’s outcome for some symptoms are reported in
figure 6.3 and figure 6.4.
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Figure 6.3: Representation of probability given by the model (nausea for breast cancer)
























The improved model developed in this chapter has been turned into a web-
based prototype composed by a PHP script, which generates an HTML page
after data is collected from HTML input form and then POSTed when user
presses the "Calculate score" button.
This prototype, available at http://bit.ly/chemo-calc, implements the
side-effects mapping model in patients receiving chemotherapy discussed
in the previous sections and it is intended to be used within the 4 cycles of
chemotherapy for patients suffering from breast, colorectal and lung cancer.
The user is asked to specify the pathology, the cycle of treatment and the
day from the beginning of cycle. The user interface is shown in figure 6.5.
Probabilities are then calculated using formula 6.1 for the specified day d
(shown as today), and also for day d+ 1 (shown as tomorrow) and d+ 2 (shown
as the day after tomorrow). Expected side-effects are shown if probability is
greater than 20% and are classified as "very likely" if greater than 40% or
"likely" otherwise. An example of the output is reported in figure 6.6.
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Stirling Chemotherapy Side-Effects Model
Side-effects mapping model in patients with lung, colorectal 
and breast cancer receiving chemotherapy
Chemotherapy is a frequently used treatment in people with cancer and it can cause a number of 
side-effects which if not properly managed could have a negative impact on the patients' quality of 
life. Predicting side-effects will help medical and nursing staff caring for such patients and selecting 










3. Day:  
 
Developed by Thomas Mazzocco and Amir Hussain, University of Stirling. All rights reserved. 
Pilot prototype provided "as is" without any warranty. 
1
Calculate
Figure 6.5: Input screen for chemotherapy side-effects model
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Stirling Chemotherapy Side-Effects Model
Side-effects mapping model in patients with lung, colorectal 
and breast cancer receiving chemotherapy
Based on the information provided, expected side effects are reported below.
Today very likely: • nausea (50%)










Very likely side effects have a probability of occurring greater than 40%.
Likely side effects have a probability of occurring greater than 20%.
Side effects with a lower probability of occurring are not reported.
Back 
Developed by Thomas Mazzocco and Amir Hussain, University of Stirling. All rights reserved. 
Pilot prototype provided "as is" without any warranty. 
Figure 6.6: Output example for chemotherapy side-effects model
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6.7 discussion
The main aim of this case study was to improve results produced by previous
state-of-the-art models for prediction of side-effect symptoms experienced by
patients with breast cancer receiving adjuvant chemotherapy, extending the
model also for colorectal and lung cancers.
The model combines, for the first time, the two empirically determined
effects: specifically the peak effect and the inverted U-shape effect, for which
two different functions were chosen by trial and error.
From the analysis of chosen performance metrics, the model seems to have
generally reached the envisaged performance providing an average increase of
19% in comparison with the previous model: this demonstrates the potential
of these kinds of models in the management of chemotherapy related toxicities
within clinical practice. Some limitations should also be noted: first, the
considered sample of patients was not so large and was not equally distributed
between breast, colorectal and lung cancer; a second limitation relates to the
fact that the available data covered just four cycles of chemotherapy, while
most adjuvant breast cancer chemotherapy regimens consist of six to eight
cycles; finally, data about different administered treatments are not available
at present.
The proposed framework in section 3.5 recommended to carry out a mis-
classification analysis only for classification problems, so such analysis has not
been performed for this case study.
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A range of contributions and potential impact is envisaged from this work
both for clinical practice and further research. On clinical practice, patients
could know in advance which symptom they should expect and when, and
health professionals could take appropriate action wherever possible in order
to avoid or, at least, minimize expected discomforts.
From the point of view of future research in this interdisciplinary area, a
comprehensive model has been proposed for time series symptom analysis:
which is expandable with different non-linear basis functions and the applied
framework has also shown how to select possible variables which require to
be considered or excluded to improve the model giving, as a by-product, some
new insights on symptoms’ pattern within each cycle, between different cycles
and between different treatments. This added-value aspect can also be further
researched and new insights correlated with clinical findings.
6.8 conclusion
This work successfully built on a previous state-of-the-art tool for side-
effect modelling on patients with cancer undergoing adjuvant chemotherapy
treatment, following recommendations given in section 3.2. The proposed
model has been both generally improved and may be reusable in different
contexts.
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Whilst the encouraging results reported in this small-scale study should be
taken with care, they do illustrate the potential of this kind of a time series
modelling approach.
For future work, further large-scale investigations using larger datasets
can be carried out and different modelling techniques can be applied (using
different types of basis functions) with a view to providing a reliable model
that could be potentially deployed in clinical practice.
7
C O N C L U S I O N S A N D F U T U R E W O R K
7.1 conclusions
This thesis presented a sound framework for the development of CDSSs, and
in particular of the underlying predictive models, identifying best practices
for each stage of the model’s development.
As outlined throughout the thesis, clinical decision support systems have
a huge potential for leading to better care and appropriate implementations
of such systems will promote a better use of medical knowledge. Three
applications of the proposed framework have been developed.
Every step of the framework addressed specific problems emerging from
relevant literature. Whenever possible, adopted solutions have been validated
within the proposed case studies.
The first developed model predicted mortality within 28 days of patients
suffering from acute alcoholic hepatitis. A comparison generated by state
of the art tools shows an improved predictive power, demonstrating how
the inclusion of suitable variables leads to an overall improved accuracy of
the model. In this case, adopting an appropriate selection of variables, as
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suggested by the developed framework, increased the predictive power of
the model by 25% when compared to the widely used mDF, CPS and GAHS
scores.
The second developed predictive model was designed to aid the early
diagnosis of dementia, improving on the performance of a recent application
of Bayesian belief networks [80] by means of a novel approach based on
logistic regression. Our model, which adopts a statistical selection of variables
according to the proposed general framework, outperformed the model which
used variables selected by domain experts in previous studies. The obtained
results outperform considered benchmarks by 15%.
The third built model predicted the probability of experiencing a certain
symptom among common side-effects in patients receiving chemotherapy. The
newly developed model included a pre-modelling stage, which was based on
previous research studies [110], and a subsequent regression. The accuracy
of the predictive results (computed on a daily basis for each cycle of therapy)
shows that the newly proposed approach has enhanced its predictive power by
19% when compared to the previously developed models. Such improvements
have been obtained by an appropriate usage of available a priori knowledge
to pre-model the functional forms, as suggested by the proposed framework.
The results reported in the three case studies above demonstrate the utility
of employing the proposed framework to address different kinds of problems
with the aim of improving existing models and developing new predictive
models. Such improvements are clearly envisaged to have an impact both on
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clinical practice and further research. In particular, in terms of clinical impact,
the proposed applications are expected to 1) help identify patients suffering
from acute episodes of AH who may benefit from aggressive intervention to
improve their survival rate, 2) aid the early diagnosis of dementia conditions,
and 3) deliver better symptom management for patients suffering from breast,
colorectal and lung cancer. Also, these three case studies may also be extended
clinically, to validate the inclusion/exclusion of specific variables and to
improve the predictive power in identified areas with a high presence of
misclassifications.
7.2 future work
In terms of future work, large-scale studies are required to clinically validate
the results from the presented case studies and to assess the feasibility of
deploying such models in real clinical practice.
Also, the adoption of different cost functions may enhance regression based
systems: as discussed, type I and type II errors can have different costs. With
reference to the proposed case studies, it is reasonable to hypothesize that
the cost of not identifying a patient (suffering from AH) who may benefit
from aggressive intervention can be different from the cost of administering
an aggressive treatment to a patient who could be treated with standard
medications: this difference could for example be estimated by the mortality
rate among the two groups of patients receiving the wrong treatments. Also,
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the cost of further investigating possible early dementia conditions could
generally differ from the cost of treating the same conditions at advanced
stages following an incorrect early diagnosis: this difference could for example
be estimated by the monetary costs of different medical examinations and
treatments, as well as by other indicators measuring the patient’s expected
quality of life.
Further investigations may be able to determine such cost differences
and implement an appropriate cost function in order to minimize overall
“costs” of system misclassifications: resulting models will take into account
the costs of false positives and false negatives. It is worth noticing that for
a logistic regression model, the modification of the cost function could be
quite straightforward (e.g. by multiplying each of the two addends of the
summation reported in formula B.4 for the actual misclassification cost).
Also, different strategies for dealing with misclassifications should be invest-
igated: the limited size of the considered datasets did not allow for the design
of ensemble classifiers system, i.e. systems with two or more classification
steps. As shown, misclassifications may not be uniformly distributed and,
when this occurs, it is possible to isolate areas where the developed model
is not accurate: in such areas, the system does not provide the user with any
recommendation. This strategy, while increasing the overall predictive power
of the model by reducing the overall number of misclassifications, also reduces
the number of cases in which the model itself could be used.
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It may be possible to build more complex models (or based on different vari-
ables) in the identified areas with a view to identifying different relationships
between input and output. This could have a locally better predictive power
when compared to the original model: further investigations are required to
study whether this strategy could lead to more powerful systems able to cope
also with areas where regressions fail to give accurate results.
Finally, the work presented in this thesis focused on regression models.
Other machine learning techniques were not covered in this work, as they
have not been used in the applications developed within this thesis essentially
due to limitations imposed by the size of available datasets. Also, some of
these techniques (such as neural networks or support vector machines) may
not be able to clearly justify the relationship between the provided input and
the model output. Some other techniques (e.g. decision trees) may be able to
overcome this limitation, however they require a level of technical expertise
which may prevent clinical researchers from using them. Future research
studies should investigate how to extend and adapt the proposed framework
in order to be used with other machine learning techniques.
A
I N F O R M AT I O N A N D C O M M U N I C AT I O N T E C H N O L O G Y
U S A G E I N PAT I E N T S
Chapter 2 explored few aspects of the development process of models behind
CDSSs: specifically, the chapter presented an investigation of the role of
knowledge in such systems and how new medical knowledge could be
extracted from data mining process. Key features for the successful integration
of CDSSs in the actual clinical workflows were then presented. Finally, the
focus was on how such models have been developed in the recent past,
specifically using logistic regression, identifying common pitfalls in published
works and suggesting a possible general framework for developing and
evaluating such systems.
This appendix investigates the possibility of deployment of CDSSs to
patients in order to improve healthcare, for example leading to a better
symptom management, improving patients’ quality of life, reducing number
of visits and hospitalization, saving money and time resources.
Specifically, this analysis presents the results of a study which assessed
the perceived usage of, and attitudes toward, communication technologies
(i.e. mobile phone and texting, e-mail, and the internet) in patients attending
a cardiology clinic with a view to understanding whether CDSSs may be
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successfully deployed to patients and then guiding future health service
redesign.
This study was performed in a remote regional hospital serving both
urban and rural populations. A questionnaire was completed by a sample
of 221 patients attending a general cardiology clinic. The questions asked
about patients’ access to and use of technology at home. Data collected also
included age, gender, travel time to the clinic, mode of travel, and whether the
respondent was accompanied to the clinic. Appropriate statistical tests were
used with significance taken at the 0.05 level.
As probably expected, it has been ascertained that age was the strongest
predictor of use of communication technologies, with younger patients more
likely to use e-mail, web, mobile phone, and texting. However, frequency of
use of e-mail was not related to age and an encouraging 99% of patients used
at least one communication technology.
a.1 communication technologies for healthcare
Ensuring equal access to good quality healthcare should be a core aim of
each national health system. Effective communication between patients and
healthcare staff is key to the delivery of this aim. Traditionally, communication
occurs by face-to-face contact or written correspondence. However, there
has been increasing interest in the use of simple digital communication
technologies (including mobile phone and texting, e-mail, and the internet).
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These technologies have the potential to be more rapid, responsive, and
cost-effective in improving the quality of healthcare by enhancing the level
of communication across organizational boundaries of healthcare provision,
such as the primary-secondary care interface. Communication problems across
this interface have long been identified as a source of frustration to patients
and clinicians alike [112]. Furthermore, studies have shown that using such
technologies can produce care clinically similar to that from face-to-face
consultations with health professionals, improve patients’ access to care, and
reduce hospital and travel costs [113]. Overcoming geographical barriers to
access is one of the principal challenges for providing health services to remote
and rural areas [114].
However, despite the promise of the "digital age", its full potential in terms
of healthcare and improved access to healthcare is not currently being realized.
This is likely because of a variety of reasons, including technology limitations,
although lack (or perceived lack) of technology skills and confidence in both
patients and healthcare providers remains a major barrier to more widespread
use [115, 116].
There has been a considerable increase in the use of communication technolo-
gies within the general public, and while it might be assumed that general skill
levels are high, there are few published data on patients’ knowledge and skills
in this area. Specific training may overcome skills deficiency, but it remains
likely that the successful widespread implementation of new technologies
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into healthcare services will depend in a large part on the existing abilities of
patients and healthcare providers.
In this appendix, we aim to assess the perceived usage of, and attitudes
toward, communication technologies (mobile phone and texting, e-mail, and
the internet) in patients attending a cardiology clinic with a view to guiding
future health service redesign.
a.2 methodology
Raigmore Hospital is situated in the north of Scotland (Highland Region)
and serves a population of over 300,000 dispersed over a large geographical
area (10,085 square miles). Approximately 70% of patients live within 1-hour
travel time from the major hospital with good roads and public transport, but
much of the rest of the population have considerable geographical hurdles
to attending the clinic, including transport by plane and ferry from island
locations. There are no peripheral specialist cardiology clinics in this area,
and therefore all patients travel to Raigmore Hospital for specialist cardiology
review.
A self-completion questionnaire-based survey was conducted on a con-
venience sample of patients attending a general cardiology clinic between
February and May 2009. All patients attending the clinic were included, and
questionnaires were distributed by the clerical staff at the clinic. These were
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adult patients (>16 years old) with a range of cardiologic conditions. This
included "new" and "return" patients.
In the absence of a validated instrument a questionnaire was developed in
several iterative stages including a pilot study. The results from this pilot study
allowed further questionnaire redesign until the final version was agreed upon.
The questions asked about patients’ access to and use of technology at home.
Most questions required a yes/no response or used a 4-point rating scale.
Respondent data included age, gender, travel time to the clinic, mode of travel,
and whether the respondent was accompanied to the clinic.
Data were transposed from self-completed paper questionnaires into a
spreadsheet. The p-values using an appropriate statistical test were used to
assess the influence of age (unpaired t-test), gender (chi-squared test), and
distance from the hospital (unpaired t-test) on the use of the internet, mobile
phone, text messages, and e-mail. For testing frequencies of usage for each
technology analysis of variance was used. Significance was taken at the 0.05
level.
a.3 results from questionnaire
In total, 221 patient responses were studied: 124 of them (57%) were male. The
average age was 62.1 ± 14.1 years (range: 16-89 years). The self-reported places
of residence were as follows: countryside, 40 (18%); city, 77 (35%); town, 36
(16%); and village, 68 (31%). The median travel time to hospital was 30 min
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(range: 0-1 h). The majority (172, i.e. 78%) of patients used private transport
to attend hospital, 23 (10%) used public transport, and 7 (3%) used hospital
transport or ambulance.
The majority of patients had a CD or DVD player at home: 166 (75%) and
163 (74%), respectively. Many patients (136, i.e. 62%) had a home computer,
and 111 (50%) reported having broadband access. With regard to patients’
overall use of the four means of communication technologies, 14.0% never use
two out of the four, 14.7% never use three out of the four, and only 0.7% never
use any.
Gender and distance from the main urban center were not related to use
of the Internet or mobile phone usage (or mobile texting function) (all p >
0.05). However, age was closely correlated with usage of communication tech-
nologies. On average, participants who used the communication technology
were younger than those who did not for the Internet (56 ± 14 versus 68 ±
10; p < 0.001), mobile phone (59 ± 14 versus 73 ± 12 years; p < 0.001), mobile
texting function (54 ± 13 versus 68 ± 10; p < 0.001), and e-mail (56 ± 14 versus
69 ± 11 years; p < 0.001). Furthermore, age was found to be a key factor in
determining the frequency of use of mobile phones (p < 0.001) and texting (p
< 0.001) but not the frequency of using the internet (p = 0.43) and e-mail (p =
0.76).
Many respondents (80, i.e. 36%) reported a wish to contact a doctor or nurse
between clinic appointments by e-mail, 93 (42%) did not wish to do this, and
the remainder did not respond to this question. Patients who had a computer
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at home were much more likely to wish to use e-mail between appointments
compared with those patients without a computer at home (76/136, i.e. 56%
versus 3/78, i.e. 4%; p < 0.001). Once again, age was a key factor in determining
whether patients desired to use e-mail to contact a doctor or nurse (p < 0.001).
a.4 analysis of results
Increased use of communication technologies has the potential to improve
patient care [117]. Implementation of these can be difficult, and patient skills
and confidence with them will vary. Within the variables investigated in
the present study, age was the strongest predictor of use of communication
technologies (mobile phone and texting, e-mail, and Internet). Age was also a
predictor of frequency of use of mobile phone and texting but not for e-mail
and Internet. Patients who lived in more remote areas were no more likely to
use communication technologies than those who lived in more urban areas.
Successful and widespread implementation of communication technologies in
healthcare is likely to depend on part on the availability within the general
public. In our cohort only 62% of patients had a home computer, and only 50%
had broadband connectivity, and this is likely to limit the immediate ability
to develop web or e-mail based healthcare solutions to the majority of our
population. However, the proportion of younger patients with computers is
much higher, and as this cohort of patient ages there will be an increase in the
proportion of patients with access to computers and mobile phones and the
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skills to use them. The potential benefits for the delivery of healthcare services
by greater use of technology are considerable. Traditional face-to-face medical
outpatient clinics are a common way of assessment and monitoring patients
and have been in place for many years, but many patients are seen in the
clinic with little or no positive outcome in terms of treatment decisions, with
some patients being seen as a matter of routine [118]. Alternative methods for
reviewing patients may include telephone consultations, telemedicine, e-mail,
or other web-based communication. These are of particular interest in remotes
areas where long distances can exist between patients and their healthcare
providers.
Access to healthcare professionals is more difficult in remote areas for a
variety of reasons [119]. The most recent Scottish Household Survey highlights
that less than half of people in remote rural areas find access to hospital
outpatient departments "very or fairly convenient"; public transport is also
an issue, with 51% of remote and rural areas stating public transport services
are convenient compared with 88% in large urban areas and 79% in accessible
small towns [114]. Distance from specialists and specialist facilities - for
example, cardiac catheterization facilities - is inversely proportional to the
likelihood of patients receiving specialist investigation [120]. In some cases (e.g.
chronic heart failure) this can result in poorer outcomes for patients in remote
areas [121]. However, there is an increasing awareness that technology may
help overcome barriers to healthcare delivery and equity of access particularly
in remote areas [122].
A.4 analysis of results 152
Teleclinics and communication technology use may be of most benefit to
rural patients in that they greatly reduce or abolish travel times. Instead of
patients requiring days off work to attend a clinic, they can potentially receive
specialist clinical review via videoconferencing at a local venue. Furthermore,
between formal clinic appointment times, it may be difficult to reach a
physician at a convenient time for both physician and patient. The use
of e-mail or web-based communication may better enable communication
between the patient and the doctor, obviating the necessity of both parties
being available at the same time. This potentially could increase adherence
to treatment plans and thus improve overall health. In one study in patients
with congestive cardiac failure, the introduction of telemedicine increased
medication compliance and improved physical and mental well-being at a
relatively low cost [123]. In cases where individuals do not have Internet
access the nearest healthcare centers may facilitate contact between the patient
and hospital doctors, and where there is a lack of patient skills this could be
facilitated by local healthcare professionals (e.g. community nurses).
Acceptability of new services will be important in their subsequent imple-
mentation. The use of text messages to remind patients for hospital appoint-
ments in pediatric services in Hull resulted in a decrease in nonattendance.
It is important that over 90% of these patients were happy to receive a
text reminder of appointments. With regard to videoconsultations a review
of patients using psychiatric services noted that some patients preferred
videoconferencing compared with traveling to the clinic [124]. Although
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some individuals perceive such appointments as impersonal, they felt that an
adequate doctor-patient relationship was established. This was particularly the
case in patients who were previously known to the doctor where a relationship
had been formed prior to the videoconferencing appointment, suggesting that
videoconferencing may be more appropriate for review patients rather than
new patient consultations. Nevertheless, the benefits of more frequent or
convenient communication with a doctor appeared to be more important than
potential subtle reductions in quality of consultation (i.e. the patients were
less affected by the way in which doctors interacted with them but rather
whether this interaction occurred at all) [125]. However, telecommunication is
obviously less robust in terms of physical examination, and there is a danger
that physical signs will be missed [126]. Furthermore, patients and physicians
share some concerns regarding communication technology [127]. Security and
confidentiality are a particular concern with e-mail and web. Physicians report
concern regarding developing a good rapport with patients and the danger
of missing nonverbal queues, although case selection should reduce these
risks. In some instances physicians feared that the introduction of telemedicine
would increase clinical workload. This concern was surrounding the hours
that would be spent reviewing e-mails and responding to individuals [128].
Good documentation of working practice and appropriately supported service
redesign should address these issues.
This current study has demonstrated that older patients are less likely to use
communication technologies in day-to-day living, and there is a concern that
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older patients will be denied the benefits from using healthcare technologies.
However, studies have shown that if support is given, new technologies
can be successfully used even in very elderly populations [126]. Another
concept is that of "teleassistance" where individuals in the community facilitate
communication between physicians via telemedicine; these individuals could
be community nurses, general practitioners, or others, although using non-
healthcare professionals may be ethically challenging, and confidentiality of
patients should always be protected.
The use of technology in daily life is likely to continue to increase and with it
the proportion of the population with specific communication technology skills.
Already there are many examples of the use of communication technology in
the delivery of healthcare (e.g. mobile phones, online booking, NHS repeat
prescriptions service). However, many of these technologies have been used
in younger patients (e.g. young diabetic patients) and therefore may not be
so easily implemented in a general clinic population: indeed, in our cohort
age was the dominant influence on the use of communication technologies.
Furthermore, high-tech monitoring of patients both in the hospital and in a
non-hospital setting will continue to be developed [129, 130].
This was a single center study, and therefore the results may not be applic-
able to other centers. Nevertheless this was a study of all comers and therefore
represented a breadth of patients in terms of age and geographical locations.
Indeed, although other studies have investigated the use of technologies in
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younger patients, our cohort was unselected and therefore represents a more
general cardiac clinic population.
a.5 conclusion
This study has identified that the use of communication technologies is not
widespread within the cardiology outpatient community. Age is the strongest
predictor of use of communication technology, with younger patients more
likely to use e-mail, the web, mobile phone, and texting. This study has
highlighted that there may be several potential barriers to the widespread
implementation of communication technology to a general cardiology clinic
population. Cognizance should be taken of these findings when attempting
service redesign.
B
M AT H E M AT I C A L F O R M U L AT I O N O F R E G R E S S I O N S
A N D G R A D I E N T D E S C E N T
Regression analysis is a statistical method to determine the relationship
between a dependent variable and a number of independent variables. Details
about functional forms, cost functions and a minimization algorithm are
reported in the following sections.
b.1 linear regression
For linear regression, the relationship between input vector X and output is
determined by the function f defined as follows:
f(B,X) = BTX (B.1)
where X is the vector of predictor variables (with 1 as first element).
Given a training set withM data points
{
(X(1),y(1)), (X(2),y(2)) · · · (X(M),y(M))
}






(BTX(m) − y(m))2 (B.2)
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b.2 logistic regression
The model output is the probability f(B,X) of a data point belonging to a
certain class given known values of X (vector containing predictors). The
general form of the functional dependence is expressed by formula 2.1 and






where X is the vector of predictor variables (with 1 as first element) and B is
the vector of coefficients to be determined by the logistic regression algorithm.
Given a training set withM data points
{
(X(1),y(1)), (X(2),y(2)) · · · (X(M),y(M))
}
with X(m) ∈ Rn+1, x(m)0 = 1 and y(m) ∈ {0, 1}, the cost function J(B) to be







y(m) log f(B,X(m)) + (1− y(m)) log (1− f(B,X(m)))] (B.4)
b.3 gradient descent
In order to minimize the cost function an iterative methods is used: for example,
the gradient descent algorithm could be used to carry out such task and few
details are here reported.
Given a first solution guess B[0] and a learning rate α, coefficients at the









B.3 gradient descent 158
That is:
B[k+1] = B[k] −α∇J(B[k]) (B.6)




B I B L I O G R A P H Y
[1] T. Mazzocco, A. Hussain, S. Hussain, and A. A. Shah, “A novel mortality
model for acute alcoholic hepatitis including variables recorded after
admission to hospital,” Computers in biology and medicine, vol. 44, pp. 132–
135, 2014.
[2] T. Mazzocco and A. Hussain, “Novel logistic regression models to aid
the diagnosis of dementia,” Expert Systems with Applications, vol. 39, no. 3,
pp. 3356–3361, 2012.
[3] T. Mazzocco and A. Hussain, “A side-effects mapping model in patients
with lung, colorectal and breast cancer receiving chemotherapy,” in e-
Health Networking Applications and Services (Healthcom), 2011 13th IEEE
International Conference on, pp. 34–39, IEEE, 2011.
[4] T. Gandiya, A. Dua, G. King, T. Mazzocco, A. Hussain, and S. J. Leslie,
“Self-reported “communication technology” usage in patients attending
a cardiology outpatient clinic in a remote regional hospital,” Telemedicine
and e-Health, vol. 18, no. 3, pp. 219–224, 2012.
[5] G. Goertzel, “Clinical decision support system,” Annals of the New York
Academy of Sciences, vol. 161, no. 2, pp. 689–693, 1969.
159
bibliography 160
[6] V. Sintchenko and H. Garsden, “Clinical decision support: new ap-
proaches to usability study,” HIC 2002: Proceedings: Improving Quality by
Lowering Barriers, p. 32, 2002.
[7] H. Kaur and S. K. Wasan, “Empirical study on applications of data
mining techniques in healthcare,” Journal of Computer Science, vol. 2,
no. 2, p. 194, 2006.
[8] D. Avison and T. Young, “Time to rethink health care and ICT?,”
Communications of the ACM, vol. 50, pp. 69–74, 2007.
[9] M. Ashworth, P. Seed, D. Armstrong, S. Durbaba, and R. Jones, “The
relationship between social deprivation and the quality of primary care:
a national survey using indicators from the UK quality and outcomes
framework,” British Journal of General Practice, vol. 57, pp. 441–448, 2007.
[10] J. Gammon, M. Heulwen, and D. Gould, “A review of the evidence for
suboptimal compliance of healthcare practitioners to standard/universal
infection control precautions,” Journal of Clinical Nursing, vol. 17, pp. 157–
167, 2007.
[11] D. F. Lobach, “Electronically distributed, computer-generated, individu-
alized feedback enhances the use of a computerized practice guideline,”
in Proceedings of the AMIA Annual Fall Symposium, p. 493, American
Medical Informatics Association, 1996.
[12] D. K. Litzelman, R. S. Dittus, M. E. Miller, and W. M. Tierney, “Requir-
ing physicians to respond to computerized reminders improves their
bibliography 161
compliance with preventive care protocols,” Journal of general internal
Medicine, vol. 8, no. 6, pp. 311–317, 1993.
[13] D. Hunt, R. Haynes, S. Hanna, and K. Smith, “Effects of computer-based
clinical decision support systems on physician performance and patient
outcomes: a systematic review,” The Journal of the American Medical
Association, vol. 280, pp. 1339–1346, 1998.
[14] A. X. Garg, N. K. Adhikari, H. McDonald, M. P. Rosas-Arellano, P. Dever-
eaux, J. Beyene, J. Sam, and R. B. Haynes, “Effects of computerized
clinical decision support systems on practitioner performance and
patient outcomes,” JAMA: the journal of the American Medical Association,
vol. 293, no. 10, pp. 1223–1238, 2005.
[15] E. S. Berner, Clinical Decision Support Systems. Springer, 2007.
[16] W. B. Kannel, D. McGee, and T. Gordon, “A general cardiovascular risk
profile: the Framingham study,” The American journal of cardiology, vol. 38,
no. 1, pp. 46–51, 1976.
[17] C. Hug, Detecting hazardous intensive care patient episodes using real-time
mortality models. PhD thesis, Massachusetts Institute of Technology, 2009.
[18] E. Coiera, “Clinical decision support systems,” Guide to health informatics,
vol. 2, no. 1, 2003.
[19] M. J. Rantz, M. Skubic, R. J. Koopman, L. Phillips, G. L. Alexander, S. J.
Miller, and R. D. Guevara, “Using sensor networks to detect urinary tract
bibliography 162
infections in older adults,” in e-Health Networking Applications and Services
(Healthcom), 2011 13th IEEE International Conference on, pp. 142–149, IEEE,
2011.
[20] K. Kawamoto, C. A. Houlihan, E. A. Balas, and D. F. Lobach, “Improving
clinical practice using clinical decision support systems: a systematic
review of trials to identify features critical to success,” Bmj, vol. 330,
no. 7494, p. 765, 2005.
[21] P. S. Roshanov, N. Fernandes, J. M. Wilczynski, B. J. Hemens, J. J. You,
S. M. Handler, R. Nieuwlaat, N. M. Souza, J. Beyene, H. G. C. V. Spall,
A. X. Garg, and R. B. Haynes, “Features of effective computerised clinical
decision support systems: meta-regression of 162 randomised trials,”
BMJ, vol. 346, 2013.
[22] C. M. Clancy and K. Cronin, “Evidence-based decision making: global
evidence, local decisions,” Health affairs, vol. 24, no. 1, pp. 151–162, 2005.
[23] V. Patkar, D. Acosta, T. Davidson, A. Jones, J. Fox, and M. Keshtgar,
“Cancer multidisciplinary team meetings: evidence, challenges, and the
role of clinical decision support technology,” International journal of breast
cancer, vol. 2011, 2011.
[24] A. Wright, D. W. Bates, B. Middleton, T. Hongsermeier, V. Kashyap,
S. M. Thomas, and D. F. Sittig, “Creating and sharing clinical decision
support content with web 2.0: issues and examples,” Journal of biomedical
informatics, vol. 42, no. 2, pp. 334–346, 2009.
bibliography 163
[25] R. Scales and M. Embrechts, “Computational intelligence techniques for
medical diagnostics,” in Proceedings of Walter Lincoln Hawkins, Graduate
Research Conference from the World Wide Web: http://www. cs. rpi. edu/˜
bivenj/MRC/proceedings/papers/researchpaper. pdf, 2002.
[26] K. C. Desouza, “Knowledge management in hospitals: a process oriented
view and staged look at managerial issues,” International journal of
healthcare technology and management, vol. 4, no. 6, pp. 478–497, 2002.
[27] S. K. Wasan, V. Bhatnagar, and H. Kaur, “The impact of data mining
techniques on medical diagnostics,” Data Science Journal, vol. 5, pp. 119–
126, 2006.
[28] K. J. Ottenbacher, H. R. Ottenbacher, L. Tooth, and G. V. Ostir, “A review
of two journals found that articles using multivariable logistic regres-
sion frequently did not report commonly recommended assumptions,”
Journal of clinical epidemiology, vol. 57, no. 11, pp. 1147–1152, 2004.
[29] J. Concato, A. R. Feinstein, and T. R. Holford, “The risk of determining
risk with multivariable models,” Annals of internal medicine, vol. 118,
no. 3, pp. 201–210, 1993.
[30] S. C. Bagley, H. White, and B. A. Golomb, “Logistic regression in the
medical literature: standards for use and reporting, with particular
attention to one medical domain,” Journal of clinical epidemiology, vol. 54,
no. 10, pp. 979–985, 2001.
bibliography 164
[31] S. Kotsiantis, D. Kanellopoulos, and P. Pintelas, “Data preprocessing
for supervised learning,” International Journal of Computer Science, vol. 1,
no. 2, pp. 111–117, 2006.
[32] D. B. Suits, “Use of dummy variables in regression equations,” Journal of
the American Statistical Association, vol. 52, no. 280, pp. 548–551, 1957.
[33] C. Dougherty, Introduction to econometrics, vol. 2. Oxford University Press
Oxford, 2002.
[34] A. Field, Discovering Statistics Using SPSS 3th (third) edition. Sage
Publications Ltd, 2010.
[35] A. R. Feinstein, Multivariable analysis: an introduction. Yale University
Press, 1996.
[36] R. L. Ott, M. Longnecker, and L. Ott, A first course in statistical methods.
Thomson-Brooks/Cole, 2004.
[37] S. Menard, Applied logistic regression analysis. No. 106, Sage, 2002.
[38] R. H. Myers, Classical and modern regression with applications, vol. 2.
Duxbury Press Belmont, CA, 1990.
[39] G. H. John, R. Kohavi, K. Pfleger, et al., “Irrelevant features and the
subset selection problem,” in ICML, vol. 94, pp. 121–129, 1994.
[40] D. P. MacKinnon, J. L. Krull, and C. M. Lockwood, “Equivalence of
the mediation, confounding and suppression effect,” Prevention Science,
vol. 1, no. 4, pp. 173–181, 2000.
bibliography 165
[41] M. A. Babyak, “What you see may not be what you get: a brief,
nontechnical introduction to overfitting in regression-type models,”
Psychosomatic medicine, vol. 66, no. 3, pp. 411–421, 2004.
[42] J. Concato and A. R. Feinstein, “Monte Carlo methods in clinical research:
applications in multivariable analysis,” Journal of investigative medicine:
the official publication of the American Federation for Clinical Research, vol. 45,
no. 6, p. 394, 1997.
[43] F. E. Harrell Jr, K. L. Lee, D. B. Matchar, T. A. Reichert, et al., “Regression
models for prognostic prediction: advantages, problems, and suggested
solutions,” Cancer treatment reports, vol. 69, no. 10, pp. 1071–1077, 1985.
[44] P. Peduzzi, J. Concato, E. Kemper, T. R. Holford, and A. R. Feinstein,
“A simulation study of the number of events per variable in logistic
regression analysis,” Journal of clinical epidemiology, vol. 49, no. 12,
pp. 1373–1379, 1996.
[45] R. Kohavi, “A study of cross-validation and bootstrap for accuracy
estimation and model selection,” in IJCAI, vol. 14, pp. 1137–1145, 1995.
[46] B. Efron, “Bootstrap methods: another look at the jackknife,” The annals
of Statistics, pp. 1–26, 1979.
[47] J.-H. Kim, “Estimating classification error rate: repeated cross-validation,
repeated hold-out and bootstrap,” Computational Statistics & Data Ana-
lysis, vol. 53, no. 11, pp. 3735–3745, 2009.
bibliography 166
[48] T. Fawcett, “An introduction to ROC analysis,” Pattern recognition letters,
vol. 27, no. 8, pp. 861–874, 2006.
[49] E. Lidbrink, J. Elfving, J. Frisell, and E. Jonsson, “Neglected aspects
of false positive findings of mammography in breast cancer screening:
analysis of false positive cases from the Stockholm trial,” BMJ, vol. 312,
pp. 273–276, 1996.
[50] M. Nano, J. Kollias, G. Farshid, P. Gill, and M. Bochner, “Clinical impact
of false-negative sentinel node biopsy in primary breast cancer,” British
Journal of Surgery, vol. 11, pp. 1430–1434, 2002.
[51] I. Gram, E. Lund, and S. Slenker, “Quality of life following a false
positive mammogram,” British Journal of Cancer, vol. 62, pp. 1018–1022,
1990.
[52] M. Zweig and G. Campbell, “Receiver-operating characteristic (ROC)
plots: a fundamental evaluation tool in clinical medicine,” Clinical
Chemistry, vol. 39, pp. 561–577, 1993.
[53] S. Sougioultzis, E. Dalakas, P. C. Hayes, and J. N. Plevris, “Alcoholic
hepatitis: from pathogenesis to treatment,” Current Medical Research and
Opinion, vol. 21, no. 9, pp. 1337–1346, 2005. PMID: 16197651.
[54] M. Fox, J. Fox, and M. Davies, “Diagnosis and management of chronic
liver disease in older people,” Reviews in Clinical Gerontology, vol. 21,
pp. 1–15, 2 2011.
bibliography 167
[55] R. Bruha, K. Dvorak, and J. Petrtyl, “Alcoholic liver disease,” World
journal of hepatology, vol. 4, no. 3, p. 81, 2012.
[56] W. C. Maddrey, J. K. Boitnott, M. S. Bedine, F. L. Weber Jr, E. Mezey,
R. I. White Jr, et al., “Corticosteroid therapy of alcoholic hepatitis,”
Gastroenterology, vol. 75, no. 2, pp. 193–199, 1978.
[57] R. N. H. Pugh, I. M. Murray-Lyon, J. L. Dawson, M. C. Pietroni, and
R. Williams, “Transection of the oesophagus for bleeding oesophageal
varices,” British Journal of Surgery, vol. 60, no. 8, pp. 646–649, 1973.
[58] C. Child, “Ill: The liver and portal hypertension,” Philadelphia, WB
Saunders Co, p. 23, 1964.
[59] E. H. Forrest, C. D. J. Evans, S. Stewart, M. Phillips, Y. H. Oo, N. C.
McAvoy, N. C. Fisher, S. Singhal, A. Brind, G. Haydon, J. O’Grady,
C. P. Day, P. C. Hayes, L. S. Murray, and A. J. Morris, “Analysis of
factors predictive of mortality in alcoholic hepatitis and derivation and
validation of the Glasgow alcoholic hepatitis score,” Gut, vol. 54, no. 8,
pp. 1174–1179, 2005.
[60] W. Dunn, L. H. Jamil, L. S. Brown, R. H. Wiesner, W. R. Kim, K. V. N.
Menon, M. Malinchoc, P. S. Kamath, and V. Shah, “MELD accurately
predicts mortality in patients with alcoholic hepatitis,” Hepatology, vol. 41,
no. 2, pp. 353–358, 2005.
[61] A. Duseja, N. S. Choudhary, S. Gupta, R. K. Dhiman, and Y. Chawla,
“Apache ii score is superior to sofa, ctp and meld in predicting the short-
bibliography 168
term mortality in patients with acute-on-chronic liver failure (ACLF),”
Journal of Digestive Diseases, pp. 484–490, 2013.
[62] M. Sheth, M. Riggs, and T. Patel, “Utility of the Mayo End-Stage Liver
Disease (MELD) score in assessing prognosis of patients with alcoholic
hepatitis,” BMC gastroenterology, vol. 2, no. 1, p. 2, 2002.
[63] A. Chedid, C. Mendenhall, P. Gartside, S. French, T. Chen, and L. Rabin,
“Prognostic factors in alcoholic liver disease. A cooperative study group,”
The American journal of gastroenterology, vol. 86, pp. 210–216, 02 1991.
[64] S. Masson, I. Emmerson, E. Henderson, E. Fletcher, A. Burt, C. Day,
and S. Stewart, “PWE-285 Clinical but not histological factors predict
long-term prognosis in patients with biopsy proven advanced alcoholic
liver disease,” Gut, vol. 61, no. Suppl 2, pp. A413–A414, 2012.
[65] L. Castera, “Noninvasive methods to assess liver disease in patients with
hepatitis B or C,” Gastroenterology, vol. 142, pp. 1293–1302.e4, 05 2012.
[66] W. Srikureja, N. L. Kyulo, B. A. Runyon, and K.-Q. Hu, “MELD score is a
better prognostic model than Child-Turcotte-Pugh score or Discriminant
Function score in patients with alcoholic hepatitis,” Journal of Hepatology,
vol. 42, no. 5, pp. 700 – 706, 2005.
[67] W. Maddrey, “Alcoholic liver disease,” Current hepatology, vol. 1, pp. 71–
85, 1995.
bibliography 169
[68] P. Mathurin, C. L. Mendenhall, R. L. C. Jr, M.-J. Ramond, W. C.
Maddrey, P. Garstide, B. Rueff, S. Naveau, J.-C. Chaput, and T. Poynard,
“Corticosteroids improve short-term survival in patients with severe
alcoholic hepatitis (AH): individual data analysis of the last three
randomized placebo controlled double blind trials of corticosteroids
in severe AH,” Journal of Hepatology, vol. 36, no. 4, pp. 480 – 487, 2002.
[69] T. F. Imperiale and A. J. McCullough, “Do corticosteroids reduce
mortality from alcoholic hepatitis? A meta-analysis of the randomized
trials,” Annals of Internal Medicine, vol. 113, no. 4, pp. 299–307, 1990.
[70] “Management of patients with dementia: a national clinical guideline,”
tech. rep., Scottish Intercollegiate Guidelines Network, 2006.
[71] S. Turner, S. Iliffe, M. Downs, J. Wilcock, M. Bryans, E. Levin, J. Keady,
and R. O’Carroll, “General practitioners’ knowledge, confidence and
attitudes in the diagnosis and management of dementia,” Age and ageing,
vol. 33, no. 5, pp. 461–467, 2004.
[72] S. Cahill, M. Clark, H. O’Connell, B. Lawlor, R. Coen, and C. Walsh,
“The attitudes and practices of general practitioners regarding dementia
diagnosis in Ireland,” International journal of geriatric psychiatry, vol. 23,
no. 7, pp. 663–669, 2008.
[73] E. C. Hansen, C. Hughes, G. Routley, and A. L. Robinson, “General
practitioners’ experiences and understandings of diagnosing dementia:
bibliography 170
factors impacting on early diagnosis,” Social science & medicine, vol. 67,
no. 11, pp. 1776–1783, 2008.
[74] S. Klöppel, C. M. Stonnington, J. Barnes, F. Chen, C. Chu, C. D. Good,
I. Mader, L. A. Mitchell, A. C. Patel, C. C. Roberts, et al., “Accuracy of
dementia diagnosis: a direct comparison between radiologists and a
computerized method,” Brain, vol. 131, no. 11, pp. 2969–2974, 2008.
[75] M. J. Prince, J. L. de Rodriguez, L. Noriega, A. Lopez, D. Acosta,
E. Albanese, R. Arizaga, J. R. Copeland, M. Dewey, C. P. Ferri, et al.,
“The 10/66 dementia research group’s fully operationalised DSM-IV
dementia computerized diagnostic algorithm, compared with the 10/66
dementia algorithm and a clinician diagnosis: a population validation
study,” BMC Public Health, vol. 8, no. 1, p. 219, 2008.
[76] M. Prince, C. P. Ferri, D. Acosta, E. Albanese, R. Arizaga, M. Dewey, S. I.
Gavrilova, M. Guerra, Y. Huang, K. Jacob, et al., “The protocols for the
10/66 dementia research group population-based research programme,”
BMC Public Health, vol. 7, no. 1, p. 165, 2007.
[77] L. Oteniya, R. Coles, and J. Cowie, “DemNet: a clinical decision
support system to aid the diagnosis of dementia,” in Proceedings of
the 22ndHealthCare Computing Conference, pp. 289–297, Citeseer, 2005.
[78] F. V. Jensen and T. D. Nielsen, Bayesian networks and decision graphs.
Springer, 2007.
bibliography 171
[79] J. Cowie, L. Oteniya, and R. Coles, “Diagnosis of dementia and its
pathologies using Bayesian belief networks,” in ICEIS (2), pp. 291–295,
2006.
[80] L. Oteniya, Bayesian belief networks for dementia diagnosis and other
applications: a comparison of hand-crafting and construction using a novel data
driven technique. PhD thesis, University of Stirling, 2008.
[81] R. Petersen, J. Stevens, M. Ganguli, E. Tangalos, J. Cummings, and
S. DeKosky, “Practice parameter: early detection of dementia. Mild
cognitive impairment (an evidence-based review). Report of the quality
standards subcommittee of the American Academy of Neurology,”
Neurology, vol. 56, no. 9, pp. 1133–1142, 2001.
[82] H. Brodaty and C. M. Moore, “The clock drawing test for dementia of the
Alzheimer’s type: a comparison of three scoring methods in a memory
disorders clinic,” International journal of geriatric psychiatry, vol. 12, no. 6,
pp. 619–627, 1997.
[83] J. Moroney, E. Bagiella, D. Desmond, V. C. Hachinski, P. Mölsä, L. Gust-
afson, A. Brun, P. Fischer, T. Erkinjuntti, W. Rosen, et al., “Meta-analysis
of the Hachinski Ischemic Score in pathologically verified dementias,”
Neurology, vol. 49, no. 4, pp. 1096–1105, 1997.
[84] S. Daskalaki, I. Kopanas, and N. Avouris, “Evaluation of classifiers for an
uneven class distribution problem,” Applied artificial intelligence, vol. 20,
no. 5, pp. 381–417, 2006.
bibliography 172
[85] D. D. R. Cox, The analysis of binary data, vol. 32. CRC Press, 1989.
[86] N. J. Nagelkerke, “A note on a general definition of the coefficient of
determination,” Biometrika, vol. 78, no. 3, pp. 691–692, 1991.
[87] Cancer statistics: registrations, England, 2007. Office for National Statistics,
2009.
[88] Cancer Incidence. ISD Scotland (NHS), 2010.
[89] Cancer Incidence in Wales, 2003-2007. Public Health Wales, 2009.
[90] Cancer Incidence and Mortality. Northern Ireland Cancer Registry, 2009.
[91] The Diagnosis and Treatment of Lung Cancer. National Collaborating Centre
for Cancer, Cardiff (Wales), 2005.
[92] Early and locally advanced breast cancer: diagnosis and treatment. National
Collaborating Centre for Cancer, Cardiff (Wales), 2009.
[93] A. Molassiotis, C. Stricker, B. Eaby, L. Velders, and P. Coventry, “Un-
derstanding the concept of chemotherapy-related nausea: the patient
experience,” European Journal of Cancer Care, vol. 17, pp. 444–453, 2008.
[94] N. Kuderer, D. Dale, J. Crawford, L. Coser, and G. Lyman, “Mortality,
morbidity, and cost associated with febrile neutropenia in adult cancer
patients,” Cancer, vol. 106, pp. 2258–2266, 2006.
[95] G. Bonadonna, P. Valaguassa, A. Moliterni, and C. Brambilla, “Adjuvant
cyclophosphamide, methotrexate, and fluorouracil in node positive
bibliography 173
breast cancer patients: the results of 20 years of follow-up,” The New
England Journal of Medicine, vol. 332, pp. 901–906, 1995.
[96] D. Carr, L. Goudas, D. Lawrence, W. Pirl, J. Lau, D. DeVine, B. Kulpelnick,
and K. Miller, “Management of cancer symptoms: pain, depression, and
fatigue,” tech. rep., Agency for Healthcare Research and Quality, 2002.
[97] M. Groenvold, P. Fayers, M. Petersen, M. Sprangers, N. Aaronson, and
H. Mouridsen, “Breast cancer patients on adjuvant chemotherapy report
a wide range of problems not identified by health-care staff,” Breast
Cancer Research and Treatment, vol. 103, pp. 185–195, 2007.
[98] M. Jefford and M. H. Tattersall, “Informing and involving cancer patients
in their own care,” The Lancet Oncology, vol. 3, pp. 629–637, 2002.
[99] E. L. Poleshuck, J. Katz, C. H. Andrus, L. A. Hogan, B. F. Jung, D. I.
Kulick, and R. H. Dworkin, “Risk factors for chronic pain following
breast cancer surgery: a prospective study,” The Journal of Pain, vol. 7,
pp. 626–634, 2006.
[100] J. Armer, M. Radina, D. Porock, and S. Culbertson, “Predicting breast
cancer-related lymphedema using self-reported symptoms,” Nursing
Research, vol. 52, pp. 370–379, 2003.
[101] J. A. Talcott, J. Manola, J. A. Clark, I. Kaplan, C. J. Beard, S. P. Mitchell,
R. C. Chen, M. P. O’Leary, P. W. Kantoff, and A. V. D’Amico, “Time course
and predictors of symptoms after primary prostate cancer therapy,”
Journal of Clinical Oncology, vol. 21, pp. 3979–3986, 2003.
bibliography 174
[102] G. Dranitsaris, D. Rayson, M. Vincent, J. Chang, K. Gelmon, D. Sandor,
and G. Reardon, “The development of a predictive model to estimate
cardiotoxic risk for patients with metastatic breast cancer receiving
anthracyclines,” Breast Cancer Research and Treatment, vol. 107, pp. 443–
450, 2008.
[103] A. Louis, T. Turner, M. Gretton, A. Baksh, and J. Cleland, “A systematic
review of telemonitoring for the management of heart failure,” European
Journal of Heart Failure, vol. 5, pp. 583–590, 2003.
[104] N. Kearney, L. McCann, J. Norrie, L. Taylor, P. Gray, M. McGee-Lennon,
M. Sage, M. Miller, and R. Maguire, “Evaluation of a mobile phone-based,
advanced symptom management system (ASyMS©) in the management
of chemotherapy-related toxicity,” Supportive Care in Cancer, vol. 17,
pp. 437–444, 2009.
[105] N. Kearney, L. Muir, M. Miller, I. Hargan, and P. Gray, “Using handheld
computers to support patients receiving outpatient chemotherapy,”
European Journal of Cancer Supplements, vol. 1, p. S368, 2003.
[106] R. Maguire, L. McCann, M. Miller, and N. Kearney, “Nurse’s perceptions
and experiences of using of a mobile-phone-based Advanced Symptom
Management System (ASyMS©) to monitor and manage chemotherapy-
related toxicity,” European Journal of Oncology Nursing, vol. 12, pp. 380–
386, 2008.
bibliography 175
[107] N. Kearney, L. Kidd, M. Miller, M. Sage, J. Khorrami, M. McGee,
J. Cassidy, K. Niven, and P. Gray, “Utilising handheld computers to
monitor and support patients receiving chemotherapy: results of a UK-
based feasibility study,” Supportive Care in Cancer, vol. 14, pp. 742–752,
2006.
[108] R. Maguire, M. Miller, M. Sage, J. Norrie, L. McCann, L. Taylor, and
N. Kearney, “Results of a UK based pilot study of a mobile phone
based advanced symptom management system (ASyMS©) in the remote
monitoring of chemotherapy related toxicity,” Clinical Effectiveness in
Nursing, vol. 9, pp. 202–210, 2005.
[109] L. Forbat, R. Maguire, L. McCann, N. Illingworth, and N. Kearney, “The
use of technology in cancer care: applying Foucault’s ideas to explore
the changing dynamics of power in health cares ideas to explore the
changing dynamics of power in health care,” Journal of Advanced Nursing,
vol. 65, pp. 306–315, 2009.
[110] R. Maguire, J. Cowie, C. Leadbetter, K. McCall, K. Swingler, L. McCann,
and N. Kearney, “The development of a side effect risk assessment tool
(ASyMS©-SERAT) for use in patients with breast cancer undergoing
adjuvant chemotherapy,” Journal of Research in Nursing, vol. 14, pp. 27–40,
2009.
[111] L. McCann, R. Maguire, M. Miller, and N. Kearney, “Patients’ perceptions
and experiences of using a mobile phone based Advanced Symptom
bibliography 176
Management System (ASyMS©) to monitor and manage chemotherapy
related toxicity,” European Journal of Cancer Care, vol. 18, pp. 156–164,
2009.
[112] R. Harrison, W. Clayton, and P. Wallace, “Can telemedicine be used to
improve communication between primary and secondary care?,” Bmj,
vol. 313, no. 7069, pp. 1377–1380, 1996.
[113] J. L. DelliFraine and K. H. Dansky, “Home-based telehealth: a review
and meta-analysis,” Journal of Telemedicine and Telecare, vol. 14, no. 2,
pp. 62–66, 2008.
[114] J. Deaville, The nature of rural general practice in the UK: preliminary research.
Institute of Rural Health Tregynon, Powys, 2001.
[115] S. J. Katz, N. Nissan, and C. A. Moyer, “Crossing the digital divide:
evaluating online communication between patients and their providers,”
Am J Manag Care, vol. 10, no. 9, pp. 593–598, 2004.
[116] S. J. Leslie, M. Hartswood, C. Meurig, S. P. McKee, R. Slack, R. Procter,
and M. A. Denvir, “Clinical decision support software for management
of chronic heart failure: development and evaluation,” Computers in
biology and medicine, vol. 36, no. 5, pp. 495–506, 2006.
[117] K. D. Mandl, I. S. Kohane, and A. M. Brandt, “Electronic patient-
physician communication: problems and promise,” Annals of internal
Medicine, vol. 129, no. 6, pp. 495–500, 1998.
bibliography 177
[118] M. L. Hughes, S. J. Leslie, G. K. McInnes, K. McCormac, and N. R. Peden,
“Can we see more outpatients without more doctors?,” Journal of the Royal
Society of Medicine, vol. 96, no. 7, pp. 333–337, 2003.
[119] T. Raza, M. Joshi, R. M. Schapira, and Z. Agha, “Pulmonary telemedicine:
a model to access the subspecialist services in underserved rural areas,”
International Journal of Medical Informatics, vol. 78, no. 1, pp. 53–59, 2009.
[120] M. MacLeod, A. Finlayson, J. Pell, and I. Findlay, “Geographic, demo-
graphic, and socioeconomic variations in the investigation and man-
agement of coronary heart disease in Scotland,” Heart, vol. 81, no. 3,
pp. 252–256, 1999.
[121] R. Clark, K. Eckert, S. Stewart, S. Phillips, J. Yallop, A. Tonkin, and
H. Krum, “Rural and urban differentials in primary care management
of chronic heart failure: new data from the CASE study,” Medical Journal
of Australia, vol. 186, no. 9, pp. 441–445, 2007.
[122] E. Rygh and P. Hjortdahl, “Continuous and integrated health care
services in rural areas. A literature study,” Rural and Remote Health,
vol. 7, no. 3, p. 766, 2007.
[123] P. Whitten, A. Bergman, M. A. Meese, K. Bridwell, and K. Jule, “St. Vin-
cent’s home telehealth for congestive heart failure patients,” Telemedicine
and e-Health, vol. 15, no. 2, pp. 148–153, 2009.
[124] S. Simpson, J. Knox, D. Mitchell, J. Ferguson, J. Brebner, and E. Brebner,
“A multidisciplinary approach to the treatment of eating disorders via
bibliography 178
videoconferencing in north-east Scotland,” Journal of telemedicine and
telecare, vol. 9, no. suppl 1, pp. 37–38, 2003.
[125] B. J. Wakefield, J. E. Holman, A. Ray, M. Scherubel, T. L. Burns,
M. G. Kienzle, and G. E. Rosenthal, “Outcomes of a home telehealth
intervention for patients with heart failure,” Journal of telemedicine and
telecare, vol. 15, no. 1, pp. 46–50, 2009.
[126] C. Chandhanayingyong, B. Tangtrakulwanich, and T. Kiriratnikom, “Tele-
consultation for emergency orthopaedic patients using the multimedia
messaging service via mobile phones,” Journal of telemedicine and telecare,
vol. 13, no. 4, pp. 193–196, 2007.
[127] G. King, H. Richards, and D. Godden, “Adoption of telemedicine in
Scottish remote and rural general practices: a qualitative study,” Journal
of telemedicine and telecare, vol. 13, no. 8, pp. 382–386, 2007.
[128] B. Bergeron, “E-mail: a realistic conduit for patient-doctor communica-
tions?,” The Journal of medical practice management: MPM, vol. 15, no. 4,
pp. 208–210, 1999.
[129] M. S. Manikandan and S. Dandapat, “Wavelet-based ECG and PCG
signals compression technique for mobile telemedicine,” in Advanced
Computing and Communications, 2007. ADCOM 2007. International Confer-
ence on, pp. 164–169, IEEE, 2007.
[130] M. F. A. Rasid and B. Woodward, “Bluetooth telemedicine processor
for multichannel biomedical signal transmission via mobile cellular
bibliography 179
networks,” Information Technology in Biomedicine, IEEE Transactions on,
vol. 9, no. 1, pp. 35–43, 2005.
